WO2010119955A1 - Agent pour prévenir, inhiber ou améliorer le vieillissement de la peau dû à l'accumulation de produits finaux de glycation avancée (age) - Google Patents

Agent pour prévenir, inhiber ou améliorer le vieillissement de la peau dû à l'accumulation de produits finaux de glycation avancée (age) Download PDF

Info

Publication number
WO2010119955A1
WO2010119955A1 PCT/JP2010/056853 JP2010056853W WO2010119955A1 WO 2010119955 A1 WO2010119955 A1 WO 2010119955A1 JP 2010056853 W JP2010056853 W JP 2010056853W WO 2010119955 A1 WO2010119955 A1 WO 2010119955A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
skin
advanced glycation
accumulation
end products
Prior art date
Application number
PCT/JP2010/056853
Other languages
English (en)
Japanese (ja)
Inventor
裕也 林
幸恵 武田
岳志 丹羽
賢 稲岡
Original Assignee
ロート製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2009101070A external-priority patent/JP2010248150A/ja
Priority claimed from JP2009101063A external-priority patent/JP2010248148A/ja
Application filed by ロート製薬株式会社 filed Critical ロート製薬株式会社
Priority to CN201080012136.4A priority Critical patent/CN102355884B/zh
Publication of WO2010119955A1 publication Critical patent/WO2010119955A1/fr
Priority to HK12107231.0A priority patent/HK1166601A1/xx

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations

Definitions

  • the present invention relates to an advanced glycation end product degradation agent used as a cosmetic composition or a food composition, and prevention, suppression, or improvement of skin deterioration due to accumulation of advanced glycation end products. It relates to the agent.
  • a saccharification reaction occurs between a reducing sugar such as glucose and a protein, and a saccharification product is generated.
  • Protein saccharification occurs in vivo, but if a hyperglycemic state continues due to diabetes, etc., or if the degradation reaction does not proceed easily due to aging, the production of glycation products tends to occur and the function of the protein is impaired. Saccharification products accumulate. This saccharification product finally becomes a terminal saccharification product (advanced glycation end products; hereinafter abbreviated as “AGEs”), but the generation of AGEs is an irreversible reaction.
  • the generated AGEs are excreted from the body by metabolism, but with aging, the metabolic rate becomes slower and AGEs accumulate in each tissue in the living body.
  • AGEs cause various symptoms by accumulating in each tissue in the living body or binding to AGEs receptors. For example, when AGEs are generated and accumulated in the skin (epidermis, dermis), it contributes to the deterioration of the entire skin (for example, changes in skin color such as yellowing, reduction of transparency and elasticity). In diabetic patients, AGEs caused by hyperglycemia cause complications such as cataracts, arteriosclerosis, and renal dysfunction. Therefore, in order to discharge the generated AGEs to the outside of the body, it is important to decompose the AGEs into a form that can be easily discharged outside the body.
  • Patent Document 1 describes that citrus volatile oils inhibit the production of pentosidine, which is one of AGEs.
  • Patent Document 2 describes that an extract of olive oil in ethanol has an AGEs-decomposing action and suppresses skin dullness.
  • Patent Document 3 describes a whitening agent containing an unsaturated fatty acid together with a concentration of lactic acid selected from lactic acid, alkali metal lactic acid salt or alkaline earth metal salt, and lactic acid nonmetal compound with a concentration of 5 v / v% or more. Yes.
  • An object of the present invention is to provide a novel AGEs decomposing agent, an agent for preventing, suppressing, or improving skin deterioration due to accumulation of AGEs, an agent for improving skin tension, and an agent for improving skin tone.
  • Unsaturated fatty acids, and pharmaceutically acceptable salts thereof, pharmaceutically acceptable glycerides thereof, pharmaceutically acceptable esters thereof, and pharmaceutically acceptable amides thereof (hereinafter referred to as “unsaturated”).
  • Fatty acids and their derivatives ” (sometimes abbreviated as“ fatty acids and their derivatives ”), (i) have AGEs degrading action, (ii) improve skin color changes such as yellowing, and (iii) Improve.
  • a vegetable oil comprising at least one member selected from the group consisting of unsaturated fatty acids and pharmaceutically acceptable glycerides thereof improves (i) skin tone change such as yellowish brown; (ii ) Improves skin firmness.
  • (3) at least one selected from the group consisting of lactic acid, glycolic acid, salicylic acid, malic acid, citric acid, and phytic acid, and pharmaceutically acceptable salts thereof;
  • (b) When used in combination with at least one selected from the above-mentioned unsaturated fatty acids and derivatives thereof, vegetable oils containing them, plant extracts having an AGEs-degrading effect, etc., the deterioration of the skin due to AGEs accumulation is extremely effective due to a synergistic effect.
  • the present invention has been completed based on the above findings, and has been completed.
  • the present invention provides the following AGEs degrading agents and agents for preventing, suppressing, or improving skin deterioration due to accumulation of AGEs.
  • Item 1 Unsaturated fatty acids, and pharmaceutically acceptable salts thereof, pharmaceutically acceptable glycerides thereof, pharmaceutically acceptable esters thereof, and at least one selected from the group consisting of pharmaceutically acceptable amides thereof Advanced glycation end products degradation agent containing as an active ingredient.
  • Item 2. The advanced glycation end product degradation agent according to Item 1, wherein the unsaturated fatty acid is an unsaturated fatty acid having 16 to 20 carbon atoms.
  • Item 3. Item 3.
  • the advanced glycation end product degradation agent according to Item 2 wherein the unsaturated fatty acid is at least one unsaturated fatty acid selected from the group consisting of diene unsaturated fatty acids and triene unsaturated fatty acids.
  • An advanced glycation end product degradation agent comprising as an active ingredient a vegetable oil containing at least one member selected from the group consisting of unsaturated fatty acids and pharmaceutically acceptable glycerides thereof.
  • Item 5. The advanced glycation end products decomposer according to item 4, wherein the vegetable oil is at least one vegetable oil selected from the group consisting of evening primrose oil, cariocarbradiriense fruit oil, meadowfoam oil, and shea fat.
  • the vegetable oil is at least one vegetable oil selected from the group consisting of evening primrose oil, cariocarbradiriense fruit oil, meadowfoam oil, and shea fat.
  • Item 7. The agent for preventing, suppressing or improving skin deterioration caused by accumulation of advanced glycation end products according to Item 6, wherein the unsaturated fatty acid is an unsaturated fatty acid having 16 to 20 carbon atoms.
  • the vegetable oil is at least one vegetable oil selected from the group consisting of evening primrose oil, cario carbaziriense fruit oil, meadow foam oil, and shea fat Preventing, suppressing, or improving skin deterioration.
  • Item 11 Prevention of skin deterioration caused by accumulation of advanced glycation end products according to Item 6, wherein skin deterioration caused by accumulation of advanced glycation end products is skin color change, Inhibitor or improver.
  • the advanced glycation product according to Item 6 further comprising at least one selected from the group consisting of lactic acid, glycolic acid, salicylic acid, malic acid, citric acid, and phytic acid, and pharmaceutically acceptable salts thereof.
  • the advanced glycation according to Item 9 further comprising at least one selected from the group consisting of lactic acid, glycolic acid, salicylic acid, malic acid, citric acid, and phytic acid, and pharmaceutically acceptable salts thereof.
  • at least one selected from the group consisting of lactic acid, glycolic acid, salicylic acid, malic acid, citric acid, and phytic acid, and pharmaceutically acceptable salts thereof is decomposed for advanced glycation end products.
  • An advanced group comprising a vegetable oil comprising an unsaturated fatty acid and at least one selected from the group consisting of pharmaceutically acceptable glycerides in an amount effective for degradation of advanced glycation end products to humans.
  • Application end products disassembly method.
  • Item 20 Furthermore, at least one selected from the group consisting of lactic acid, glycolic acid, salicylic acid, malic acid, citric acid, and phytic acid, and pharmaceutically acceptable salts thereof is decomposed for advanced glycation end products.
  • Item 21 The method for degrading advanced glycation end products according to Item 19, which is administered to a human in an effective amount.
  • Unsaturated fatty acids, and pharmaceutically acceptable salts thereof, pharmaceutically acceptable glycerides thereof, pharmaceutically acceptable esters thereof, and at least one selected from the group consisting of pharmaceutically acceptable amides thereof Is administered to humans in an amount effective for preventing, suppressing, or improving the deterioration of the skin caused by accumulation of advanced glycation end products. How to prevent, control or improve decline.
  • Item 23 The prevention of skin deterioration caused by accumulation of advanced glycation end products according to Item 21, wherein the deterioration of skin caused by accumulation of advanced glycation end products is skin color change, Control or improvement method.
  • at least one selected from the group consisting of lactic acid, glycolic acid, salicylic acid, malic acid, citric acid, and phytic acid, and pharmaceutically acceptable salts thereof is accumulated in advanced glycation end products.
  • a vegetable oil comprising at least one member selected from the group consisting of unsaturated fatty acids and pharmaceutically acceptable glycerides thereof is used to prevent, inhibit or improve skin deterioration caused by accumulation of advanced glycation end products.
  • Item 27 Prevention of skin deterioration caused by accumulation of advanced glycation end products according to Item 25, wherein the deterioration of skin caused by accumulation of advanced glycation end products is a reduction in skin elasticity, Control or improvement method.
  • Unsaturated fatty acids, and pharmaceutically acceptable salts thereof, pharmaceutically acceptable glycerides, pharmaceutically acceptable esters thereof, and pharmaceuticals for use in the degradation of advanced glycation end products At least one compound selected from the group consisting of pharmaceutically acceptable amides thereof.
  • a vegetable oil comprising at least one member selected from the group consisting of unsaturated fatty acids and pharmaceutically acceptable glycerides thereof for use in degrading advanced glycation end products.
  • Unsaturated fatty acids, and pharmaceutically acceptable salts, pharmaceutically acceptable salts thereof, for use in preventing, inhibiting or ameliorating skin deterioration caused by accumulation of advanced glycation end products At least one compound selected from the group consisting of glycerides, pharmaceutically acceptable esters thereof, and pharmaceutically acceptable amides thereof.
  • Item 32. The compound according to Item 31, wherein the deterioration of the skin caused by accumulation of advanced glycation end products is a change in skin color.
  • Item 32. The compound according to Item 31, wherein the deterioration of the skin caused by accumulation of advanced glycation end products is a decrease in skin elasticity.
  • Item 34 The compound according to Item 31, wherein the deterioration of the skin caused by accumulation of advanced glycation end products is a decrease in skin elasticity.
  • a composition comprising the following (a) and (b) for use in the prevention, suppression or improvement of skin deterioration due to accumulation of advanced glycation end products: (a) At least one compound selected from the group consisting of lactic acid, glycolic acid, salicylic acid, malic acid, citric acid, phytic acid, and pharmaceutically acceptable salts thereof (b) selected from the group consisting of unsaturated fatty acids, and pharmaceutically acceptable salts thereof, pharmaceutically acceptable glycerides thereof, pharmaceutically acceptable esters thereof, and pharmaceutically acceptable amides thereof At least one compound;
  • Item 35 The composition according to Item 34, wherein the deterioration of the skin caused by accumulation of advanced glycation end products is a change in skin color.
  • Item 36 The composition according to Item 34, wherein the deterioration of the skin caused by accumulation of advanced glycation end products is a change in skin color.
  • Item 35 The composition according to Item 34, wherein the deterioration of the skin due to accumulation of advanced glycation end products is a decrease in skin elasticity.
  • Item 37 At least one selected from the group consisting of unsaturated fatty acids and pharmaceutically acceptable glycerides thereof for use in the prevention, suppression or amelioration of skin deterioration due to accumulation of advanced glycation end products. Vegetable oil containing seeds.
  • Item 38. The vegetable oil according to Item 37, wherein the deterioration of skin caused by accumulation of advanced glycation end products is a change in skin color.
  • the vegetable oil according to Item 37 wherein the deterioration of the skin caused by accumulation of advanced glycation end products is a decrease in skin elasticity.
  • Item 40 A composition comprising the following (a) and (b) for use in the prevention, suppression or improvement of skin deterioration due to accumulation of advanced glycation end products: (a) At least one compound selected from the group consisting of lactic acid, glycolic acid, salicylic acid, malic acid, citric acid, phytic acid, and pharmaceutically acceptable salts thereof (b) A vegetable oil comprising at least one member selected from the group consisting of unsaturated fatty acids and pharmaceutically acceptable glycerides thereof 41. Item 41.
  • composition according to Item 40 wherein the deterioration of the skin caused by accumulation of advanced glycation end products is a change in skin color.
  • Item 41. The composition according to Item 40, wherein the deterioration of the skin caused by accumulation of advanced glycation end products is a decrease in skin elasticity.
  • Item 43. Unsaturated fatty acids, and pharmaceutically acceptable salts thereof, pharmaceutically acceptable glycerides thereof, pharmaceutically acceptable esters thereof, and at least one selected from the group consisting of pharmaceutically acceptable amides thereof For the production of advanced glycation end products degradation agents.
  • a vegetable oil comprising at least one member selected from the group consisting of an unsaturated fatty acid and a pharmaceutically acceptable glyceride thereof for the production of an advanced glycation end products degradation agent.
  • Item 45 Unsaturated fatty acids, and pharmaceutically acceptable salts thereof, pharmaceutically acceptable glycerides thereof, pharmaceutically acceptable esters thereof, and at least one selected from the group consisting of pharmaceutically acceptable amides thereof.
  • Use of a compound of the present invention for the manufacture of an agent for preventing, inhibiting or improving skin deterioration caused by accumulation of advanced glycation end products.
  • Item 45 wherein the deterioration of the skin caused by accumulation of advanced glycation end products is a change in skin color.
  • Item 46. The use according to Item 45, wherein the deterioration of the skin due to accumulation of advanced glycation end products is a decrease in skin elasticity.
  • Item 48. Use of a composition comprising the following (a) and (b) for the manufacture of an agent for preventing, suppressing or improving skin deterioration due to accumulation of advanced glycation end products.
  • At least one compound selected from the group consisting of lactic acid, glycolic acid, salicylic acid, malic acid, citric acid, and phytic acid, and pharmaceutically acceptable salts thereof (b) selected from the group consisting of unsaturated fatty acids, and pharmaceutically acceptable salts thereof, pharmaceutically acceptable glycerides thereof, pharmaceutically acceptable esters thereof, and pharmaceutically acceptable amides thereof At least one compound; Item 49.
  • the use according to Item 48, wherein the deterioration of the skin caused by accumulation of advanced glycation end products is a change in skin color.
  • Item 49. The use according to Item 48, wherein the deterioration of the skin caused by accumulation of advanced glycation end products is a decrease in skin elasticity.
  • Item 51 An agent for preventing, suppressing, or improving skin deterioration caused by accumulation of advanced glycation end products of vegetable oil containing at least one member selected from the group consisting of unsaturated fatty acids and pharmaceutically acceptable glycerides thereof Use for manufacturing.
  • Item 52. Item 52. The use according to Item 51, wherein the deterioration of the skin due to accumulation of advanced glycation end products is a change in skin color.
  • Item 52. The use according to Item 51, wherein the deterioration of the skin due to accumulation of advanced glycation end products is a decrease in skin elasticity.
  • Item 54 An agent for preventing, suppressing, or improving skin deterioration caused by accumulation of advanced glycation end products of vegetable oil containing at least one member selected from the group consisting of unsaturated fatty acids and pharmaceutically acceptable glycerides thereof Use for manufacturing.
  • Item 52. The use according to Item 51, wherein the deteriorati
  • compositions comprising the following (a) and (b) for the manufacture of an agent for preventing, suppressing or improving skin deterioration due to accumulation of advanced glycation end products.
  • a vegetable oil comprising at least one member selected from the group consisting of unsaturated fatty acids and pharmaceutically acceptable glycerides thereof 55.
  • Item 55 The use according to Item 54, wherein the deterioration of the skin caused by accumulation of advanced glycation end products is a change in skin color.
  • Item 55 The use according to Item 54, wherein the deterioration of the skin caused by accumulation of advanced glycation end products is a decrease in skin elasticity.
  • Unsaturated fatty acids and derivatives thereof have an action of degrading AGEs. This action improves, suppresses and / or prevents the deterioration of the entire skin caused by the accumulation of AGEs in the skin (for example, changes in skin color such as yellowish dullness, decreased transparency and elasticity) It is possible to slow down the progress of the overall skin decline. Vegetable oils rich in unsaturated fatty acids and their derivatives have similar effects. More specifically, the improvement, suppression and / or prevention of the deterioration of the entire skin caused by the accumulation of AGEs will be described.
  • Unsaturated fatty acids and their derivatives, and vegetable oils containing these for example, evening primrose oil, Cariocarbra gliense fruit
  • a cosmetic composition containing oil, Meadowfoam oil, shea fat, etc. By applying a cosmetic composition containing oil, Meadowfoam oil, shea fat, etc.) to the skin or ingesting a food composition containing these, the yellowness of the skin color is suppressed, and the transparency is increased. Improves skin firmness. Thereby, the impression of the whole skin is kept young and a youthful appearance is obtained. Also, prevent or improve various diseases caused by AGEs (diabetic complications (cataract, arteriosclerosis, renal dysfunction, retinopathy, neuropathy, etc.), arteriosclerosis, malignant tumor, bone disease, Alzheimer's disease, Parkinson's disease, etc. Is expected to do.
  • AGEs diabetic complications (cataract, arteriosclerosis, renal dysfunction, retinopathy, neuropathy, etc.), arteriosclerosis, malignant tumor
  • compositions can be suitably used as a cosmetic composition.
  • (A) Agent for preventing, suppressing, or improving the deterioration of skin due to accumulation of the first AGEs of the present invention and the agent for degrading the AGEs of the present invention Preventing, suppressing, or improving skin deterioration (i) selected from the group consisting of unsaturated fatty acids, and pharmaceutically acceptable salts thereof, pharmaceutically acceptable glycerides thereof, pharmaceutically acceptable esters thereof, and pharmaceutically acceptable amides thereof At least one, or (ii) A vegetable oil containing at least one selected from the group consisting of unsaturated fatty acids and pharmaceutically acceptable glycerides thereof is included as an active ingredient.
  • the components (i) and (ii) above are also anti-glycation agents, anti-aging agents based on anti-glycation action, or active ingredients of anti-aging agents.
  • AGEs decomposing agents containing both (i) and (ii) as active ingredients, and agents for preventing, suppressing or improving skin deterioration due to accumulation of AGEs are also included in the present invention.
  • unsaturated fatty acids and derivatives thereof include unsaturated fatty acids having 16 to 24 carbon atoms. Specifically, crotonic acid (C4: 1 (2)), myristoleic acid (C14: 1 (9)), palmitoleic acid (C16: 1 (9)), oleic acid (C18: 1 (9)), Elaidic acid (C18: 1 (9)), vaccenic acid (C18: 1 (11)), gadoleic acid (C20: 1 (9)), eicosenoic acid (C20: 1 (11)), erucic acid (C22: 1 (13)), monoene unsaturated fatty acids such as nervonic acid (24: 1 (15)); linoleic acid (C18: 2 (9,12)), 8,11-icosadienoic acid (C20: 2 (8,11 ), Diene unsaturated fatty acids such as docosadienoic acid (C22: 2 (13,16)); (9,12,15) -linolenic acid
  • unsaturated fatty acids having 16 to 20 carbon atoms are preferable, unsaturated fatty acids having 18 to 20 carbon atoms are more preferable, and unsaturated fatty acids having 18 carbon atoms are even more preferable in view of high AGE decomposition activity.
  • unsaturated fatty acids having 16 to 20 carbon atoms are preferable, unsaturated fatty acids having 18 to 20 carbon atoms are more preferable, and unsaturated fatty acids having 18 carbon atoms are even more preferable in view of high AGE decomposition activity.
  • a diene unsaturated fatty acid or a triene unsaturated fatty acid is preferable in terms of high AGE decomposition activity.
  • a diene or triene unsaturated fatty acid having 18 carbon atoms is preferred.
  • pharmaceutically acceptable derivatives of unsaturated fatty acids can also be used.
  • Derivatives include salts, glycerides, esters, and amides.
  • Examples of pharmaceutically acceptable salts of unsaturated fatty acids include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; ammonium salts and the like.
  • the pharmaceutically acceptable glyceride of the unsaturated fatty acid may be any of monoglyceride, diglyceride and triglyceride.
  • the monoglyceride may be any of 1-acyl glyceride, 2-acyl glyceride and 3-acyl glyceride.
  • the diglyceride may be any of 1,2-acyl glyceride, 1,3-acyl glyceride and 2,3-acyl glyceride.
  • the glyceride of the unsaturated fatty acid is diglyceride or triglyceride
  • at least one of the constituent fatty acids may be an unsaturated fatty acid, and the ratio of the unsaturated fatty acid in the fatty acid constituting the glyceride is preferably 30% by weight or more. 50 wt% is more preferable, and 65 wt% or more is even more preferable.
  • the unsaturated fatty acid may be the same or different.
  • Examples of pharmaceutically acceptable esters of unsaturated fatty acids include esters with aliphatic alcohols having 1 to 20 carbon atoms.
  • Examples of pharmaceutically acceptable amides of unsaturated fatty acids include ammonia, alkylamine (alkyl group having 1 to 4 carbon atoms), dialkylamine (alkyl group having 1 to 4 carbon atoms), and trialkylamine (alkyl group). May be an amide of an unsaturated fatty acid with an alkanolamine (the alkyl group has 1 to 4 carbon atoms).
  • An unsaturated fatty acid and its derivative can be used individually by 1 type or in combination of 2 or more types.
  • Vegetable oils vegetable oils containing at least one selected from the group consisting of unsaturated fatty acids and pharmaceutically acceptable glycerides thereof, specifically evening primrose oil, cario carbaziriense fruit oil, meadow foam oil , Shea fat, avocado oil, olive oil, persic oil, cucumber nut oil, grape seed oil, safflower oil, almond oil, corn oil, pistachio seed oil, sunflower oil, hazelnut oil, macadamia nut oil, rosehip oil, soybean oil, sesame oil , Wheat germ oil, rapeseed oil, cottonseed oil, rice bran oil and the like.
  • evening primrose oil, cario carbagiriense fruit oil, meadow foam oil, and shea fat are preferable
  • evening primrose oil and cario carbagiriense fruit oil are more preferable
  • evening primrose oil is even more preferable.
  • Evening primrose oil is a fatty oil obtained from the seeds of evening primrose (Akabanae evening primrose) or a plant belonging to the same genus
  • Cariocarbrasiliense fruit oil is a fatty oil obtained from the pulp of Cariocarbrasiliense.
  • the crude oil can be obtained by mechanically squeezing seeds and the like to squeeze out the oil, further extracting the remaining oil with a solvent such as hexane, and then completely removing the solvent by distillation.
  • crude oil is obtained by adding water to the crude oil to separate the gum and removing it with a centrifuge. Phosphoric acid is added to this crude oil to remove the remaining gum, sodium hydroxide is added to remove free fatty acids, water is washed, and activated clay is added and stirred to adsorb pigments such as chlorophyll.
  • any of crude oil, crude oil, and refined oil can be used as an active ingredient for preventing, suppressing, or improving the deterioration of skin due to accumulation of AGEs and AGEs.
  • refined evening primrose oil can be purchased from, for example, Oriza Oil Chemical Co., Ltd., Nisshin Oillio Group Co., Ltd., etc.
  • vegetable oils in which the ratio of unsaturated fatty acids having 18 carbon atoms is 90% by weight or more based on the total fatty acids can also be used as an active ingredient of AGEs degradation inhibitors.
  • examples of such vegetable oil include evening primrose oil.
  • a vegetable oil can be used individually by 1 type or in combination of 2 or more types.
  • Cosmetic composition The AGEs decomposing agent of the present invention and the preventive, suppressing, or improving agent for skin deterioration due to the accumulation of the first AGEs of the present invention are known as the above-mentioned effective ingredients as cosmetic ingredients. It can be mixed with the above base or carrier to make a composition for external use, particularly a cosmetic composition. When each agent of this invention contains 2 or more types of active ingredients, it is good also as a formulation which prepares each component as a separate composition, and combined those compositions.
  • the form of the cosmetic composition is not particularly limited.
  • lotion, milky lotion, cream, cosmetic liquid, sunscreen cosmetics basic cosmetics such as packs, hand creams, body lotions, body creams; Cosmetics for cleaning such as makeup remover, body shampoo, shampoo, rinse; makeup cosmetics such as foundation, makeup base, lip balm, lipstick, cheek color; bathing agent and the like.
  • the content of the active ingredient in the cosmetic composition may be, for example, about 0.00001 to 70% by weight, preferably about 0.0001 to 50% by weight, and more preferably about 0.001 to 30% by weight.
  • Bases or carriers include paraffin, liquid paraffin, squalane, white wax, gelled hydrocarbons (such as plastibase), ozokerite, ceresin, petrolatum, hard fat, microcrystalline wax, ⁇ -olefin oligomer, light liquid paraffin, etc.
  • Hydrocarbons fatty acids such as lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, isostearic acid; glyceryl tri-2-ethylhexanoate (trioctanoin), tri (caprylic acid / capric acid) glyceryl Tri-fatty acid glycerides; higher alcohols such as cetanol, stearyl alcohol, behenyl alcohol; methyl polysiloxanes, highly polymerized methyl polysiloxanes, dimethyl siloxane methyl (polyoxyethylene) siloxane methyl (Polyoxypropylene) siloxane copolymer, dimethylsiloxane methyl (polyoxyethylene) siloxane copolymer, dimethylsiloxane methyl (polyoxypropylene) siloxane copolymer, polyoxyethylene methyl polysiloxane copolymer, poly (Oxyethylene / oxypropylene
  • hydrocarbons especially ⁇ -olefin oligomers, squalane, light liquid paraffin, liquid paraffin
  • trifatty acid glycerides especially glyceryl tri-2-ethylhexanoate, tri (caprylic acid / capric acid) glyceryl
  • higher alcohols In particular, cetanol, stearyl alcohol, behenyl alcohol
  • silicone oil especially methylpolysiloxane, alkyl acrylate copolymer methylpolysiloxane ester, cross-linked methylpolysiloxane, decamethylcyclopentasiloxane, ethyltrisiloxane, methyltrimethicone
  • Methyl siloxane network polymer polyoxyethylene / methyl polysiloxane copolymer, methyl hydrogen polysiloxane, triethoxysilylethyl polydimethylsiloxyethyl hexyl dime
  • the cosmetic composition may be a known additive added to the cosmetic, for example, a surfactant, a thickener, a preservative, a pH adjuster, a chelating agent, a stable agent, as long as the effects of the present invention are not impaired.
  • a surfactant for example, a surfactant, a thickener, a preservative, a pH adjuster, a chelating agent, a stable agent, as long as the effects of the present invention are not impaired.
  • An agent, a stimulus reducing agent, a preservative, a colorant, a dispersant, a fragrance, a pearl luster imparting agent, and the like can be added.
  • An additive can be used individually by 1 type or in combination of 2 or more types.
  • surfactant examples include sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, diglycerol sorbitan penta-2-ethylhexylate, and diglycerol sorbitan tetra-2-ethylhexylate.
  • Sorbitan fatty acid esters such as glyceryl monostearate and glyceryl monostearate; polyglyceryl fatty acids such as polyglyceryl monostearate, polyglyceryl monoisostearate and polyglyceryl diisostearate; propylene glycol monostearate Propylene glycol fatty acid esters such as: polyoxyethylene hydrogenated castor oil 40 (HCO-40), polyoxyethylene hydrogenated castor Hardened castor oil derivatives such as oil 50 (HCO-50), polyoxyethylene hardened castor oil 60 (HCO-60), polyoxyethylene hardened castor oil 80; polyoxyethylene (20) sorbitan monolaurate (polysorbate 20), Polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene (20) sorbitan monostearate (polysorbate 60), polyoxyethylene (20) sorbitan monooleate (polysorbate 80), polyoxyethylene (20) sorbitan isostearate; Polyoxyethylene hydrogenated castor oil 40 (
  • glycerin fatty acids particularly glyceryl monostearate
  • polyglycerin fatty acids particularly polyglyceryl monostearate
  • hardened castor oil derivatives particularly polyoxyethylene hardened castor oil 50 (HCO-50), polyoxyethylene) Hardened castor oil 60 (HCO-60)
  • polyoxyethylene sorbitan fatty acid esters particularly polyoxyethylene (20) sorbitan isostearate, polyoxyethylene (20) sorbitan monostearate (polysorbate 60)
  • polyoxyalkylene Alkyl ether especially polyoxyethylene cetyl ether
  • silicone surfactant especially polyoxyethylene methylpolysiloxane copolymer, lauryl PEG-9 polydimethylsiloxyethyl dimethicone, PEG-9 polydimethyl) Tylsiloxyethyl dimethicone is preferred.
  • thickener examples include guar gum, locust bean gum, carrageenan, xanthan gum, dextran, methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, sodium alginate, propylene glycol alginate, polyvinyl Alcohol, polyvinyl pyrrolidone, polyvinyl methyl ether, carboxy vinyl polymer, alkyl methacrylate copolymer, sodium polyacrylate, polyethylene glycol, bentonite, dextrin fatty acid ester, pectin, (hydroxyethyl acrylate / acryloyldimethyltaurine Na) copolymer , Methyl distearyl ammonium hectorite, (ammonium acryloyldimethyltaurate / vinylpyrrolidone) copolymer, polyethylene glycol distearate, triisostearate
  • xanthan gum alkyl methacrylate methacrylate copolymer, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol, carboxyvinyl polymer, (hydroxyethyl acrylate / acryloyldimethyltaurine Na) copolymer, dimethyl distearyl ammonium hectorite (Acryloyl dimethyl taurate ammonium / vinyl pyrrolidone) copolymer, polyethylene glycol distearate, ethylene glycol triisostearate, polyoxyethylene (20) methyl glucoside triisostearate.
  • Preservatives and preservatives include benzoic acid, sodium benzoate, dehydroacetic acid, sodium dehydroacetate, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, butyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, paraoxybenzoic acid
  • examples include benzyl, methyl paraoxybenzoate, and phenoxyethanol. Of these, methyl paraoxybenzoate, propyl paraoxybenzoate, and phenoxyethanol are preferable.
  • pH adjusters include inorganic acids (hydrochloric acid, sulfuric acid, phosphoric acid, polyphosphoric acid, boric acid, etc.), organic acids (lactic acid, acetic acid, citric acid, sodium citrate, tartaric acid, malic acid, succinic acid, sodium succinate, Oxalic acid, gluconic acid, fumaric acid, propionic acid, acetic acid, aspartic acid, epsilon-aminocaproic acid, glutamic acid, aminoethylsulfonic acid, etc.), gluconolactone, ammonium acetate, inorganic base (sodium bicarbonate, sodium carbonate, hydroxide) Potassium, sodium hydroxide, calcium hydroxide, magnesium hydroxide, etc.) and organic bases (monoethanolamine, triethanolamine, diisopropanolamine, triisopropanolamine, lysine, etc.).
  • Chelating agents include ethylenediaminetetraacetic acid (edetic acid), ethylenediaminetetraacetic acid salt (sodium salt (sodium edetate: Japanese Pharmacopeia, EDTA-2Na, etc.), potassium salt, etc.), phytic acid, gluconic acid, polyphosphoric acid, metalin An acid etc. are mentioned. Of these, sodium edetate is preferable.
  • the stabilizer include sodium polyacrylate, dibutylhydroxytoluene, butylhydroxyanisole and the like.
  • Examples of the irritation reducing agent include licorice extract and sodium alginate.
  • the colorant examples include inorganic pigments and natural pigments.
  • the pearl luster imparting agent examples include ethylene glycol distearate, ethylene glycol monostearate, and triethylene glycol distearate. Of these, ethylene glycol distearate is preferred.
  • the cosmetic composition can improve, suppress, and reduce the deterioration of the entire skin caused by accumulation of AGEs in the skin (for example, change in skin color such as yellowish blur, reduction in firmness and transparency), Alternatively, known anti-glycation components that can be added to cosmetics can be blended for the purpose of further enhancing the effects of the present invention, such as prevention and slowing down the progress (speed) of the deterioration of the entire skin.
  • Known anti-glycation components can be used singly or in combination of two or more.
  • Known anti-glycation components include, for example, Amler fruits, fruit juices or extracts thereof (JP 2006-028090, JP 2006-62989, etc.); L-arginine, L-lysine, hydrolyzed casein (above, JP 2001-039816); hydrolyzable tannin (JP 9-40519); carnosine, ⁇ -lipoic acid ("The latest skin diagnostic manual for beauty", Fragrance Journal, August 15, 2006 Issue): Western rose flower / ovary, hybrid rose flower / ovary / gaku / leaf / stem, age, grape leaf, oyster leaf, apple leaf, marigold flower, magnolia leaf extract Open 2006-273811); button genus plant extract, seaweed genus plant extract, genus genus plant extract, sunflower plant extract, aloe genus plant extract, amadocho genus plant extract, flax genus plant extract, Rose
  • ingredients derived from plants such as Amler, lychee, rose, maroonier, Maria thistle, Neem (especially Amler extract, lychee seed extract, rose petal extract, Maronier extract, Maria Thistle extract, Neem extract); hydrolysis Sexual tannin (particularly derived from chestnut astringent skin); L-arginine or a salt thereof; lysine or a salt thereof; carnosine; ⁇ -lipoic acid; aminoguanidine or a salt thereof;
  • the amount of the known anti-glycation component used is, for example, about 0.00001 to 10% by weight, preferably about 0.0001 to 5% by weight, more preferably about 0.001 to 5% by weight, based on the total cosmetic composition. is there.
  • the amount of the plant component used is, for example, about 0.00001 to 20% by weight, preferably about 0.0001 to 15% by weight, more preferably, based on the total amount of the cosmetic composition in terms of extracts such as extracts and essential oils. About 0.001 to 10% by weight.
  • the cosmetic composition has an antioxidant component, an anti-aging component, an anti-inflammatory component, a whitening component, a keratin softening component, a cell activation component, vitamins, a blood circulation promoting component, as long as the effects of the present invention are not hindered.
  • Other medicinal ingredients that can be added to cosmetics such as moisturizing ingredients, ingredients that prevent and / or repair DNA damage, UV-absorbing ingredients, UV-scattering ingredients, cleaning ingredients, antibacterial ingredients, and astringent ingredients it can.
  • Other medicinal ingredients can be used alone or in combination of two or more.
  • Antioxidant components include components derived from plants (eg, grapes, ginseng, comfrey, etc.); proanthocyanidins, tocopherols and derivatives thereof, ascorbic acid and derivatives thereof, hesperidin, glucosyl hesperidin, ergothioneine, sodium bisulfite, erythorbine
  • Examples thereof include acids and salts thereof, flavonoids, glutathione, glutathione peroxidase, glutathione-S-transferase, catalase, superoxide dismutase, thioredoxin, taurine, thiotaurine, and hypotaurine.
  • grape seed extract grape leaf extract, ginseng extract, comfrey leaf extract, proanthocyanidins, tocopherol and its derivatives (particularly ⁇ -tocopherol, ⁇ -tocopherol), ascorbic acid and its derivatives (particularly ascorbic acid, ascorbic acid)
  • Sodium phosphate ester magnesium ascorbate phosphate, ascorbyl tetraisopalmitate (ascorbyl tetra-2-hexyldecanoate), hesperidin, glucosyl hesperidin and ergothioneine are preferred.
  • the amount used is, for example, about 0.00001 to 10% by weight, preferably about 0.0001 to 5% by weight, and more preferably about 0.001 to 5% by weight, based on the entire cosmetic composition.
  • the amount of the plant component used is, for example, about 0.00001 to 20% by weight, preferably about 0.0001 to 15% by weight, more preferably, based on the total amount of the cosmetic composition in terms of extracts such as extracts and essential oils. About 0.001 to 10% by weight.
  • Anti-aging components include hydrolyzed soy protein, retinoids (retinol and its derivatives, retinoic acid, retinal, etc.), pangamic acid, kinetin, ursolic acid, turmeric extract, sphingosine derivatives, silicon, silicic acid, N-methyl-L- Examples include serine and mevalonolactone. Of these, hydrolyzed soy protein, retinol, retinol acetate, and retinol palmitate are preferred.
  • the amount used is preferably about 0.0001 to 10% by weight, more preferably about 0.01 to 5% by weight, based on the whole cosmetic composition.
  • Anti-inflammatory components include components derived from plants (eg Comfrey); allantoin, calamine, glycyrrhizic acid or derivatives thereof, glycyrrhetinic acid or derivatives thereof, zinc oxide, guaiazulene, pyridoxine hydrochloride, menthol, camphor, turpentine oil, indomethacin , Salicylic acid or a derivative thereof.
  • Comfrey leaf extract, allantoin, dipotassium glycyrrhizinate, and stearyl glycyrrhetinate are preferable.
  • the amount used is preferably about 0.0001 to 10% by weight, more preferably about 0.01 to 5% by weight, based on the whole cosmetic composition.
  • the amount of the plant component used is, for example, about 0.00001 to 20% by weight, preferably about 0.0001 to 15% by weight, more preferably, based on the total amount of the cosmetic composition in terms of extracts such as extracts and essential oils. About 0.001 to 10% by weight.
  • the whitening component examples include arbutin; hydroquinone; kojic acid; ellagic acid; phytic acid; lucinol; chamomile ET; ascorbic acid or a derivative thereof; vitamin E or a derivative thereof; pantothenic acid or a derivative thereof; Plant components (for example, plant extracts and essential oils).
  • arbutin, hydroquinone, kojic acid, ascorbic acid, sodium ascorbate phosphate sodium, magnesium ascorbate phosphate, ascorbyl tetraisopalmitate (ascorbyl tetra-2-hexyldecanoate) and tranexamic acid are preferable.
  • the amount used is preferably about 0.0001 to 10% by weight, more preferably about 0.01 to 5% by weight, based on the whole cosmetic composition.
  • the amount used in the case of using a plant component having a whitening effect as the whitening component is, for example, about 0.00001 to 20% by weight, preferably about 0.0001 to the total amount of the cosmetic composition in terms of extracts such as extracts and essential oils. 15% by weight, more preferably about 0.001 to 10% by weight.
  • the keratin soft component examples include lanolin, urea, phytic acid, lactic acid, lactate, glycolic acid, salicylic acid, malic acid, citric acid and the like. Of these, lactic acid, sodium lactate, glycolic acid, salicylic acid, and phytic acid are preferred.
  • the amount used when the keratin softening component is used is, for example, 0.0001 to 50% by weight, preferably about 0.001 to 50% by weight, more preferably about 0.05 to 25% by weight, based on the whole cosmetic composition.
  • Cell activation components include components derived from plants (for example, bilberry); amino acids such as ⁇ -aminobutyric acid and ⁇ -aminoproic acid; vitamins such as retinol and its derivatives, thiamine, riboflavin, pyridoxine hydrochloride, and pantothenic acids ⁇ -hydroxy acids such as glycolic acid and lactic acid; tannins, flavonoids, saponins, allantoins, and photosensitizer 301.
  • bilberry leaf extract, retinol, retinol acetate, and retinol palmitate are preferable.
  • the amount used when the cell activating component is used is preferably about 0.0001 to 10% by weight, more preferably about 0.01 to 5% by weight, based on the whole cosmetic composition.
  • the amount of the plant component used is, for example, about 0.00001 to 20% by weight, preferably about 0.0001 to 15% by weight, more preferably, based on the total amount of the cosmetic composition in terms of extracts such as extracts and essential oils. About 0.001 to 10% by weight.
  • Vitamins include retinol, retinol acetate, retinol palmitate, etc., retinal, retinoic acid, methyl retinoic acid, ethyl retinoic acid, retinol retinoic acid, d- ⁇ -tocopheryl retinoate, ⁇ -tocopheryl retinoate Vitamins such as ⁇ -tocopheryl retinoate; provitamins A such as ⁇ -carotene, ⁇ -carotene, ⁇ -carotene, ⁇ -carotene, lycopene, zeaxanthin, cryptoxanthin, echinone; ⁇ -tocopherol, ⁇ - Vitamin Es such as tocopherol, ⁇ -tocopherol, dl- ⁇ -tocopherol succinate, dl- ⁇ -tocopherol calcium succinate, ⁇ -tocopherol, tocopherol nicotinate; riboflavin, fla
  • vitamin A such as retinol, retinol acetate and retinol palmitate
  • vitamin C such as ascorbic acid, sodium ascorbate phosphate, magnesium ascorbate phosphate, ascorbyl tetraisopalmitate (ascorbyl tetra-2-hexyldecanoate)
  • Vitamin E such as ⁇ -tocopherol and tocopherol nicotinate
  • nicotinic acid such as nicotinamide
  • the amount of vitamins to be used can be appropriately selected in consideration of the feeling of use and effects on the skin. For example, about 0.001 to 30% by weight, preferably about 0.1 to 25%, based on the entire cosmetic composition. % By weight, more preferably about 0.5 to 20% by weight.
  • Examples of the blood circulation promoting component include plants (e.g. ginseng, ashitaba, arnica, ginkgo, fennel, enmelio, dutch oak, chamomile, roman chamomile, carrot, gentian, burdock, rice, hawthorn, shiitake, hawthorn, sorghum, nematode, Assembly, thyme, clove, chimney, spruce, spruce, spruce, carrot, garlic, butcher bloom, grape, button, maronier, melissa, yuzu, yokuinin, rosemary, rosehip, chimpi, touki, spruce, peach, apricot, walnut , A component derived from corn); tocopherol nicotinate, glucosyl hesperidin, hesperidin.
  • plants e.g. ginseng, ashitaba, arnica, ginkgo, fennel, enmelio, du
  • the amount of the blood circulation promoting component is, for example, about 0.00001 to 10% by weight, preferably about 0.0001 to 5% by weight, and more preferably about 0.001 to 4% by weight, based on the entire cosmetic composition.
  • the amount of the plant component used is, for example, about 0.00001 to 20% by weight, preferably about 0.0001 to 15% by weight, more preferably, based on the total amount of the cosmetic composition in terms of extracts such as extracts and essential oils. About 0.001 to 10% by weight.
  • ingredients derived from plants eg, Tigaya
  • amino acids such as alanine, serine, leucine, isoleucine, threonine, glycine, proline, hydroxyproline, glucosamine, theanine and derivatives thereof; collagen, gelatin, elastin
  • polyhydric alcohols such as glycerin, 1,3-butylene glycol, propylene glycol, polyethylene glycol, dipropylene glycol, diglycerin
  • sugar alcohols such as sorbitol
  • lecithin hydrogenated lecithin Phospholipids such as: hyaluronic acid, sodium hyaluronate, acetyl hyaluronic acid, sodium acetyl hyaluronate, heparin, chondroitin mucopolysaccharides
  • lactic acid, sodium pyrrolidone carboxylate NMF-derived components such as alanine, serine, leucine, is
  • chigaya root extract hydrolyzed collagen, hydrolyzed elastin, MPC polymer glycerin, 1,3-butylene glycol, polyethylene glycol, dipropylene glycol, diglycerin, polyoxypropylene methyl glucoside, trimethyl glycine (betaine), hydroxyethyl urea Acrylic acid / acrylamide / dimethyldiallylammonium chloride copolymer, hydrogenated lecithin, hyaluronic acid, sodium hyaluronate, acetyl hyaluronic acid, sodium acetyl hyaluronate and sorbitol are preferred.
  • the amount used is, for example, 0.001 to 10% by weight, preferably about 0.01 to 5% by weight, more preferably about 0.1 to 5% by weight, based on the entire cosmetic composition.
  • the amount of the plant component used is, for example, about 0.00001 to 20% by weight, preferably about 0.0001 to 15% by weight, more preferably, based on the total amount of the cosmetic composition in terms of extracts such as extracts and essential oils. About 0.001 to 10% by weight.
  • the component having the action of preventing and / or repairing DNA damage includes components derived from animals (eg, Artemia); components derived from plants (eg, cat's claw); DNA, DNA salts, RNA, RNA salts, etc. Examples include nucleic acid components. Of these, artemia extract and DNA-Na are preferred.
  • the amount of the component having the effect of preventing and / or repairing DNA damage is, for example, about 0.001 to 3% by weight, preferably about 0.01 to 1% by weight, based on the whole cosmetic composition. When animal components are used, the amount used is about 0.00001 to 0.1% by weight, preferably about 0.0001 to 0.01% by weight, based on the total amount of the cosmetic composition, in terms of extracts such as extracts.
  • UV-absorbing components include 2-methoxyhexyl paramethoxycinnamate, 2- [4- (diethylamino) -2-hydroxybenzoyl] benzoic acid hexyl ester, 2,4,6-tris [4- (2-ethylhexyloxycarbonyl) ) Anilino] -1,3,5-triazine, dimethoxybenzylideneoxoimidazolidinepropionate 2-ethylhexyl, 2,4-bis-[ ⁇ 4- (2-ethylhexyloxy) -2-hydroxy ⁇ -phenyl] -6- (4-methoxyphenyl) -1,3,5-triazine and the like.
  • paramethoxycinnamate 2-ethylhexyl, 2- [4- (diethylamino) -2-hydroxybenzoyl] benzoic acid hexyl ester, 2,4,6-tris [4- (2-ethylhexyloxycarbonyl) anilino]- 1,3,5-triazine is preferred.
  • Ultraviolet scattering components include inorganic compounds such as zinc oxide, titanium oxide, iron oxide, cerium oxide, zirconium oxide, titanium silicate, zinc silicate, anhydrous silicic acid, cerium silicate, hydrous silicic acid, and those inorganic compounds Coated with inorganic powders such as hydrous silicic acid, aluminum hydroxide, mica and talc, or compounded with resin powders such as polyamide, polyethylene, polyester, polystyrene and nylon, silicon oil and fatty acid aluminum salts, etc. And the like processed with.
  • inorganic compounds such as zinc oxide, titanium oxide and iron oxide, and those inorganic compounds coated with inorganic powder such as aluminum hydroxide, hydrous silicic acid, mica and talc, and silicon oil are preferable.
  • the amount used is, for example, about 0.001 to 35% by weight, preferably about 0.1 to 25% by weight, based on the entire cosmetic composition.
  • Anionic surfactants such as salts, polyoxyalkylene fatty acid amide ether sulfates, acylated isethionates, acylated taurates; amine oxides, glycerin fatty acid esters, sorbitan fatty acid esters, alkyl saccharides, polyoxyalkylene alkyl ethers, fatty acid alkanolamides ,
  • Nonionic surfactants such as polyoxyalkylene hydrogenated castor oil; mono- or di-long-chain alkyl quaternary amines having a straight-chain or branched long-chain alkyl group to which alkylene oxide may be added
  • Cationic surfactants such
  • anionic surfactants include higher fatty acid salts (particularly salts of higher fatty acids such as palmitic acid, lauric acid, myristic acid, stearic acid), N-acyl amino acid salts (particularly sodium N-lauroyl aspartate, potassium hydroxide / N-coconut oil fatty acid potassium acylglutamate, coconut oil fatty acid acylglycine sodium, myristoyl glutamic acid) is preferred.
  • nonionic surfactants fatty acid alkanolamides (particularly, coconut oil fatty acid diethanolamide, coconut oil fatty acid monoethanolamide) and amine oxides (particularly, coconut oil alkyldimethylamine oxide, lauryldimethylamine oxide) are preferable.
  • Amphoteric surfactants include imidazolinium betaines (especially 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolium betaine, N-coconut oil fatty acid acyl-N-carboxymethoxyethyl-N-carboxymethylethylenediamine disodium ) Is preferred.
  • the blending amount of the cleaning component is about 0.01 to 80% by weight, preferably about 0.1 to 60% by weight, based on the whole cosmetic composition.
  • Antibacterial components include chlorhexidine, salicylic acid, benzalkonium chloride, acrinol, ethanol, benzethonium chloride, cresol, gluconic acid and its derivatives, popidone iodine, potassium iodide, iodine, isopropylmethylphenol, triclocarban, triclosan, photosensitizer No. 101 Photosensitive element 201, paraben, phenoxyethanol, 1,2-pentanediol, alkyldiaminoglycine hydrochloride and the like.
  • benzalkonium chloride, benzethonium chloride, gluconic acid and its derivatives, isopropylmethylphenol, triclocarban, triclosan, photosensitizer 101, photosensitizer 201, paraben, phenoxyethanol, 1,2-pentanediol, alkyldiaminoglycine hydrochloride are preferred, and benzalkonium chloride, gluconic acid and its derivatives, benzethonium chloride, and isopropylmethylphenol are more preferred.
  • the amount used is preferably about 0.0003 to 10% by weight, more preferably about 0.01 to 5% by weight, based on the whole cosmetic composition.
  • the astringent component include metal salts such as alum, chlorohydroxyaluminum, aluminum chloride, allantoin aluminum salt, zinc sulfate, and potassium aluminum sulfate; organic acids such as tannic acid, citric acid, lactic acid, and succinic acid. Among these, alum, chlorohydroxyaluminum, aluminum chloride, allantoin aluminum salt, aluminum potassium sulfate, and tannic acid are preferable.
  • the amount used is, for example, about 0.0003 to 10% by weight, preferably about 0.01 to 5% by weight, more preferably about 0.01 to 5% by weight, based on the entire cosmetic composition.
  • the cosmetic composition of the present invention can be prepared by mixing and stirring each component according to a conventional method.
  • an ingredient insoluble in a cosmetic base and an oil component can be mixed and stirred in advance, and then an aqueous component can be blended and mixed and stirred again.
  • a stirrer such as a homomixer may be used to facilitate the dispersion of components insoluble in the base.
  • Examples of preferred combinations of the active ingredient of the present invention and other active ingredients include the following combinations.
  • a known anti-glycation component Amler extract, lychee seed extract, rose petal extract, maronier extract, maria thistle extract, neem extract, hydrolyzable tannin, L-arginine or salt thereof, lysine or salt thereof, Carnosine, ⁇ -lipoic acid, aminoguanidine or a salt thereof, aristine, or glucosamine;
  • antioxidant components are included, grape seed extract, grape leaf extract, ginseng extract, comfrey leaf extract, proanthocyanidins, ⁇ -tocopherol, ⁇ -tocopherol, ascorbic acid, sodium ascorbate phosphate, ascorbate phosphate ester
  • Comfrey leaf extract, allantoin, dipotassium glycyrrhizinate, or stearyl glycyrrhetinate When it contains a whitening component, arbutin, hydroquinone, kojic acid, ascorbic acid, sodium ascorbate phosphate, magnesium ascorbate phosphate, ascorbyl tetraisopalmitate (ascorbyl tetra-2-hexyldecanoate), or tranexamic acid,
  • a keratin soft component lactic acid, sodium lactate, glycolic acid, salicylic acid, or phytic acid
  • cell activation component When cell activation component is included, bilberry leaf extract, retinol, retinol acetate, or retinol palmitate, When vitamins are included, vitamins A (retinol, retinol acetate, retinol palmitate), vitamins C (ascorbic acid, sodium as
  • ginseng extract When containing a blood circulation promoting component, ginseng extract, tocopherol nicotinate, glucosyl hesperidin, or hesperidin, When moisturizing ingredients are included, chigaya root extract, hydrolyzed collagen, hydrolyzed elastin, MPC polymer glycerin, 1,3-butylene glycol, polyethylene glycol, dipropylene glycol, diglycerin, polyoxypropylene methylglucoside, trimethylglycine (betaine) ), Hydroxyethyl urea, acrylic acid / acrylamide / dimethyldiallylammonium chloride copolymer, hydrogenated lecithin, hyaluronic acid, sodium hyaluronate, acetyl hyaluronic acid, sodium acetyl hyaluronate, or sorbitol, When it contains a component having an action of preventing and / or repairing DNA damage, Artemia extract or DNA
  • an ultraviolet absorbing component or an ultraviolet scattering component is contained, 2-methoxyhexyl paramethoxycinnamate, 2- [4- (diethylamino) -2-hydroxybenzoyl] benzoic acid hexyl ester, or 2,4,6-tris [4 -(2-Ethylhexyloxycarbonyl) anilino] -1,3,5-triazine, zinc oxide, titanium oxide, iron oxide, inorganic powders of these inorganic compounds (aluminum hydroxide, hydrous silicic acid, mica, or talc) Or coated with silicone oil,
  • a cleaning component higher fatty acid salts (particularly salts of higher fatty acids such as palmitic acid, lauric acid, myristic acid, stearic acid), N-acyl amino acid salts (particularly sodium N-lauroyl aspartate, potassium hydroxide) / N-coconut oil fatty acid potassium acylglutamate, coconut oil
  • known anti-glycation components antioxidant components, anti-aging components, anti-inflammatory components, keratin softening components, cell activation components, vitamins, blood circulation promoting components, moisturizing components, prevention and / or repair of DNA damage
  • a component having an action an ultraviolet absorption or scattering component, and a cleaning component.
  • the AGEs decomposing agent of the present invention and the agent for preventing, suppressing, or improving skin deterioration due to the accumulation of the first AGEs of the present invention can be a food composition.
  • This food composition can be suitably used as a health food or a nutritional supplement (including balanced nutritional foods, supplements, etc.). Moreover, it is suitable for functional health foods (including foods for specified health use (including disease risk reduction labeling, standard specification type), foods for condition specific health use, and nutritional function foods).
  • the dosage form is not particularly limited, but since the active ingredient is an oil component, dosage forms such as soft capsules and emulsions can be mentioned, and soft capsules are preferred.
  • the above-described active ingredients may be added to other oils and fats, stabilizers, emulsifiers, dispersants, suspending agents, fragrances, thickeners, sweeteners, colorants, fragrances, preservatives, antioxidants, What is necessary is just to mix with food additives, such as an organic acid, and to formulate.
  • Formulation may be performed according to a conventional method.
  • a soft capsule is produced by using a soft capsule manufacturing machine to mix a mixture obtained by mixing an unsaturated fatty acid, a derivative thereof, and / or a vegetable oil, which is an active ingredient of the agent of the present invention, with other components as necessary. It is obtained by wrapping with a material and press-molding.
  • the emulsion is prepared by, for example, mixing an unsaturated fatty acid that is an active ingredient of the agent of the present invention, a derivative thereof, and / or a vegetable oil, an emulsifier, and other components as necessary, and this mixture and purified water. Can be obtained by mixing and stirring.
  • oils and fats include natural vegetable oils such as peanut oil, cocoa butter, rice germ oil, perilla oil, linseed oil, etc., hardened oils thereof, and glycerides of fatty acids (including medium chain fatty acids) (glycerides, diglycerides, triglycerides, etc.) , Beeswax and the like. Of these, beeswax is preferred.
  • emulsifiers examples include polyhydric alcohols such as polyethylene glycol, propylene glycol, glycerin, and sorbitol; glycerin fatty acid esters; carboxymethylcellulose sodium. Among these, glycerin, glycerin fatty acid ester, and sodium carboxymethyl cellulose are preferable.
  • thickeners include locust bean gum, guar gum, xanthan gum, tamarind gum, pectin, and carrageenan. Of these, xanthan gum is preferable.
  • sweetener examples include sucrose, fructose, maltose, erythritol, trehalose, maltitol, licorice extract, stevia processed sweetener, aspartame, acesulfame potassium, sorbitol, xylitol and the like.
  • preservative examples include benzoic acid or a salt thereof, sorbic acid or a salt thereof, butyl paraoxybenzoate, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, ethyl paraoxybenzoate, and the like.
  • Antioxidants include ascorbic acid, sodium ascorbate, ascorbic acid stearate, sodium ascorbate stearate, ascorbyl palmitate, bisulfite, sodium hyposulfite, sulfur dioxide, disodium EDTA calcium, erythorbic acid, Examples include sodium erythorbate and tocopherol. Of these, ascorbic acid, ascorbyl palmitate, and tocopherol are preferable.
  • organic acid examples include citric acid, succinic acid, tartaric acid, aspartic acid, lactic acid, malic acid, malonic acid, fumaric acid, maleic acid and the like.
  • a food additive can be used alone or in combination of two or more.
  • Other active ingredients can be added to the formulation.
  • food compositions improve the overall deterioration of the skin due to the accumulation of AGEs in the skin (for example, changes in the skin tone such as yellowishness, reduction in firmness and transparency)
  • known anti-glycation components that can be added to cosmetics can be blended. .
  • Known anti-glycation components can be used singly or in combination of two or more.
  • Known anti-glycation components include, for example, Amler fruits, fruit juices or extracts thereof (JP 2006-028090, JP 2006-62989, etc.); L-arginine, L-lysine, hydrolyzed casein (above, JP 2001-039816); hydrolyzable tannin (JP 9-40519); carnosine, ⁇ -lipoic acid ("The latest skin diagnostic manual for beauty", Fragrance Journal, August 15, 2006 Issued): Western rose flower / ovary, hybrid rose flower / ovary / gaku / leaf / stem, age, grape leaf, oyster leaf, apple leaf, marigold flower, magnolia leaf extract Open 2006-273811); button genus plant extract, seaweed genus plant extract, genus genus plant extract, sunflower plant extract, aloe genus plant extract, amadokoroko genus plant extract, flax genus plant extract, Rose plant extract , Linden plant extract, kangwei plant extract, genus plant
  • ingredients derived from plants such as Amler, lychee, rose, maroonier, Maria thistle, Neem (especially Amler extract, lychee seed extract, rose petal extract, Maronier extract, Maria Thistle extract, Neem extract); hydrolysis Sexual tannin (particularly derived from chestnut astringent skin); L-arginine or a salt thereof; lysine or a salt thereof; carnosine; ⁇ -lipoic acid; aminoguanidine or a salt thereof;
  • vitamins such as vitamin A, vitamin B, vitamin C, vitamin E, vitamin D, vitamin K; threonine, methionine, phenylalanine, Amino acids such as tryptophan, lysine, glycine, alanine, asparagine, glutamine, serine, cysteine, cystine, tyrosine, proline, hydroxyproline, aspartic acid, glutamic acid, hydroxylysine, arginine, ornithine, histidine; taurine, collagen, glucosamine, acetyl Glucosamine, hyaluronic acid , Isoflavones, polyphenols (eg, polyphenols derived from plants such as chest), etc.
  • examples of vitamin A include retinal, retinol, retinoic acid, carotene, dehydroretinal, lycopene and the like
  • examples of vitamin B include bistyamine, thiamine disulfide, thiamine dicetyl sulfate, benfotiamine, pro Sultiamine, fursultiamine, bisbenchamine, chicotiamine, octothiamine, allythiamine, thiamine propyl disulfide, thiamine tetrahydrofurfuryl disulfide, dicetiamine, bisibutiamine, thiamine monophosphate disulfide, thiamine pyrophosphate, chicotiamine, thiamineethyl disulfide, thiamine Propyl disulfide, riboflavin, flavin adenine dinucleotide, pyridoxine, pyridoxal, hydroxocobalamin
  • Examples include nocobalamin, methyl
  • vitamins D include ergocalciferol, cholecalciferol, hydroxycholecalciferol , Dihydroxycholecalciferol, dihydrotaxosterol and the like
  • vitamins E include tocopherol and its derivatives That.
  • polyphenols for example, polyphenols derived from plants such as chestnut astringent skin, grape seeds
  • soybean peptide for example, soybean peptide, hyaluronic acid, collagen peptide, elastin peptide, ceramide, lycopene, coenzyme Q10, astaxanthin, melon extract
  • Lactic acid bacteria extract for example, LFK
  • glutathione for example, glutathione
  • rutin cat's claw extract
  • red grape leaf extract hematococcus algae extract
  • ginger extract lotus germ extract
  • the material of the capsule film is not particularly limited, and examples thereof include pork skin gelatin, pork bone gelatin, fish gelatin, natural hydrophilic polymer, cow skin gelatin, and one or more of these. Can be used. Of these, pork skin gelatin, pork bone gelatin, pullulan and the like are preferable.
  • These capsule films can be produced by a known and conventional method.
  • the capsule film may contain not only raw materials derived from the above-mentioned specific animals and plants, but also oils and fats, polyhydric alcohols, surfactants, antioxidants, colorants, fragrances and the like.
  • fats and oils include soybean oil, safflower oil, olive oil, germ oil, rapeseed oil, sunflower oil, peanut oil, cottonseed oil, rice bran oil, cocoa butter, and other natural oils and hardened oils thereof, fatty acids (including medium chain fatty acids) ) Glycerides (glycerides, diglycerides, triglycerides, etc.).
  • the polyhydric alcohol include polyethylene glycol, propylene glycol, glycerin, sorbitol and the like.
  • surfactant include nonionic surfactants such as sorbitan fatty acid ester and polyglycerin fatty acid ester.
  • the colorant examples include carotenoid pigments, anthocyanin pigments, cacao pigments, anthranone pigments, caramel pigments, safflower yellow, titanium dioxide and the like.
  • carotenoid pigments anthocyanin pigments
  • cacao pigments cacao pigments
  • anthranone pigments caramel pigments
  • safflower yellow titanium dioxide and the like.
  • addition of oils and fats, polyhydric alcohols, surfactants, and / or natural pigments to the capsule film is preferable because the capsule formulation can be further stabilized.
  • Preferred combinations of the active ingredient of the present invention and other ingredients include the following combinations. If it contains other oils and fats, When it contains an emulsifier, dispersant, suspending agent, or stabilizer, glycerin, glycerin fatty acid ester, or sodium carboxymethylcellulose; When containing a thickener, xanthan gum, When containing a sweetener, sucrose, fructose, maltose, erythritol, trehalose, maltitol, licorice extract, stevia processed sweetener, aspartame, acesulfame potassium, sorbitol, or xylitol, If it contains a preservative, benzoic acid or salt thereof, sorbic acid or salt thereof, butyl paraoxybenzoate, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, or ethyl paraoxybenzoate, In the case of containing an emulsifier, dis
  • the content of the active ingredient is preferably about 10 to 60% by weight, and preferably about 20 to 50% by weight with respect to the whole food composition. % Is more preferred, and about 30-40% by weight is even more preferred. If it is in the above range, the amount of food composition that can be ingested comfortably includes an active ingredient sufficient to achieve a sufficient AGEs decomposition effect, and thus, prevention, suppression, or improvement of skin deterioration due to accumulation of AGEs. Will be.
  • this food composition can be prepared by adding the above-described active ingredients to general foods.
  • foods include milk, milk drinks, lactic acid bacteria drinks, soft drinks with fruit juice, carbonated drinks, vegetable juice drinks, tea drinks, fruit juice drinks, ion drinks, sports drinks, functional drinks, vitamin supplement drinks, and nutrition supplement balance drinks ,
  • Beverages such as jelly beverages, alcoholic beverages, soups; puddings such as custard pudding, milk pudding, pudding with fruit juice, gel-like confectionery such as jelly, dressing, cream, chewing gum, bubble gum Gum (plate gum, sugar-coated grain gum, etc.), chocolate (solid chocolate, coated chocolate, chocolate with flavor such as strawberry chocolate, blueberry chocolate, melon chocolate, etc.), soft candy (caramel, nougat, gummy candy) , Including marshmallows) Mels, biscuits (hard biscuits, soft biscuits, soft cookies, crackers, half biscuits, etc.), cakes and other confectionery; ice cream, ice milk, lacto ice, sherbet,
  • a vegetable oil comprising at least one compound selected from the group consisting of: and (ii) at least one compound selected from the group consisting of unsaturated fatty acids and pharmaceutically acceptable glycerides thereof, AGEs decomposition, or accumulation of AGEs It can be used as an active ingredient for the production of food additives for preventing, suppressing, or improving the deterioration of the skin due to.
  • the cosmetic composition may be applied to human skin (face, etc.) in the usual manner of use and number of uses.
  • the food composition may be taken so that the daily intake of the active ingredient is, for example, about 50 to 4000 mg, preferably about 50 to 500 mg, more preferably about 50 to 180 mg.
  • the subject of use of the agent for preventing, suppressing, or improving skin deterioration due to accumulation of AGEs and AGEs of the present invention is not particularly limited, but the cosmetic composition is caused by the elderly, generation of AGEs, and accumulation Suitable subjects include humans in whom the overall skin has declined, humans in whom the entire skin has a tendency to decline due to the generation and accumulation of AGEs, and the like.
  • the cosmetic composition is applied to the skin to give the active ingredient to the skin from the outside, and by ingesting the food composition, the skin is taken by the oral route. It is preferable to give an active ingredient to. That is, it is particularly suitable to use the cosmetic composition of the present invention and the food composition of the present invention in combination.
  • the present invention includes the following methods. (i) selected from the group consisting of unsaturated fatty acids, and pharmaceutically acceptable salts thereof, pharmaceutically acceptable glycerides thereof, pharmaceutically acceptable esters thereof, and pharmaceutically acceptable amides thereof Advanced glycation end products are administered in an amount effective for degradation of advanced glycation end products to humans (including application to human skin), advanced glycation end products degradation method, or non- Disassembling therapeutic advanced glycation end products.
  • a plant oil containing at least one member selected from the group consisting of unsaturated fatty acids and pharmaceutically acceptable glycerides thereof is administered to humans in an amount effective for degradation of advanced glycation end products ( Advanced glycation end products degradation method, or non-therapeutic advanced glycation end product degradation method.
  • a vegetable oil containing at least one member selected from the group consisting of unsaturated fatty acids and pharmaceutically acceptable glycerides thereof is used to reduce skin deterioration caused by accumulation of advanced glycation end products (for example, skin Advanced glycation end products accumulation in humans (including application to human skin) in an amount effective for prevention, suppression or improvement of skin tension reduction or skin color change
  • advanced glycation end products for example, skin Advanced glycation end products accumulation in humans (including application to human skin
  • the vegetable oil containing at least one member selected from the group consisting of the glycerides may cause degradation of advanced glycation end products or skin deterioration caused by accumulation of advanced glycation end products (for example, skin This is for use in the prevention, suppression, or improvement of reduction in elasticity or skin color change. It can also be used for the manufacture of advanced glycation end products degradation agents, or for the prevention, suppression or improvement of skin deterioration caused by accumulation of advanced glycation end products. it can.
  • An agent for preventing, suppressing or improving the deterioration of skin, an agent for improving skin firmness, and an agent for improving skin color include the following (a) and (b) as active ingredients.
  • (b) AGEs decomposer includes the following (bi), (b-ii), or (b-iii).
  • an improving agent an improving agent for skin tension, and an improving agent for skin tone are also included in the present invention.
  • Lactic acid, glycolic acid, salicylic acid, malic acid, citric acid, and phytic acid, and pharmaceutically acceptable salts thereof examples include alkali metal salts such as sodium salt and potassium salt; calcium Salt, alkaline earth metal salt such as magnesium salt; ammonium salt and the like.
  • alkali metal salts such as sodium salt and potassium salt
  • calcium Salt alkaline earth metal salt such as magnesium salt
  • ammonium salt and the like examples include alkali metal salts such as sodium salt and potassium salt; calcium Salt, alkaline earth metal salt such as magnesium salt; ammonium salt and the like.
  • lactic acid, glycolic acid, salicylic acid, malic acid, citric acid, and phytic acid, and pharmaceutically acceptable salts thereof lactic acid, sodium lactate, glycolic acid, salicylic acid, phytic acid are preferred, and lactic acid, sodium lactate Is more preferable.
  • Unsaturated fatty acids and derivatives thereof are as described for the AGEs decomposing agent of the present invention and the agent for preventing, suppressing, or improving skin deterioration due to accumulation of the first AGEs of the present invention.
  • Vegetable oil The vegetable oil is as described for the AGEs decomposing agent of the present invention and the agent for preventing, suppressing or improving skin deterioration due to accumulation of the first AGEs of the present invention.
  • a plant extract having an AGEs decomposing effect can be used without limitation.
  • Known plant extracts having an AGEs-degrading effect include, for example, an olive extract (Japanese Patent Laid-Open No. 2001-122758); a saxifrage extract (Japanese Patent Laid-Open No. 2001-131051); Japanese Unexamined Patent Publication No. 2007-161663); Polar Solvent Extract of Rosaceae (Japanese Unexamined Patent Publication No. 2007-161662); Polar Solvent Extract of Rooibos Plant (Japanese Unexamined Patent Publication No.
  • extracts derived from plants such as mugwort, saxifrage, carrot, hikiokoshi, brown algae, grape seed, apple, maronnier, and neem are preferable.
  • the plant extract which has an AGEs decomposition effect can be used individually by 1 type or in combination of 2 or more types.
  • Cosmetic composition Preventing, suppressing, or improving skin deterioration due to accumulation of the second AGEs of the present invention, a skin tension improving agent, and a skin color improving agent include the above-described active ingredients, It can be mixed with a known base or carrier acceptable as a cosmetic ingredient to make a cosmetic composition.
  • Each agent of the present invention may be formulated as a single composition comprising the component (a) and the component (b), and the component (a) and the component (b) are formulated as separate compositions. It may be a formulation in which these compositions are combined.
  • 2 or more types of said (a) component, or 2 or more types of said (b) component they are good also as a mutually different composition.
  • the form of the cosmetic composition is not particularly limited.
  • lotion, milky lotion, cream, cosmetic liquid, sunscreen cosmetics basic cosmetics such as packs, hand creams, body lotions, body creams; Cosmetics for cleaning such as makeup remover, body shampoo; makeup cosmetics such as foundation, makeup base, lip balm, lipstick, teak color; bathing agent and the like.
  • the content of (a) lactic acid, glycolic acid, salicylic acid, malic acid, citric acid, and phytic acid and pharmaceutically acceptable salts thereof in the cosmetic composition is, for example, about 0.0001 to 50% by weight. About 0.001 to 50% by weight is preferable, and about 0.05 to 25% by weight is more preferable.
  • the pH of the cosmetic composition containing (a) lactic acid, glycolic acid, salicylic acid, malic acid, citric acid, phytic acid, and pharmaceutically acceptable salts thereof may be, for example, 5.5 or less, The number is preferably 4 or less, and may be 2 or more, for example, and preferably 3 or more.
  • the pH of the composition may be in the above range, and the composition containing the component (a) and the component (b) When the composition containing is a different composition, the pH of the composition containing the component (a) may be in the above range.
  • the content of the (b) AGEs decomposing agent in the cosmetic composition may be, for example, about 0.00001 to 20% by weight, preferably about 0.0001 to 10% by weight, and more preferably about 0.001 to 5% by weight.
  • the total amount thereof may be in the above range.
  • a cosmetic composition comprising (a) lactic acid, glycolic acid, salicylic acid, malic acid, citric acid, and phytic acid, and pharmaceutically acceptable salts thereof, and (b) an AGEs degrading agent.
  • the ratio (component (a): component (b)) in this case is preferably about 1: 0.0000002 to 200,000, more preferably about 1: 0.000002 to 10000, and even more preferably about 1: 0.00004 to 100 by weight.
  • the combination ratio (component (a): component (b)) may be within the above range. If it is the said range, the improvement effect of sufficient skin tension and the improvement effect of the skin tone will be acquired with the normal usage-amount of cosmetics.
  • the base, carrier, or additive of the cosmetic composition is as described for the AGEs decomposing agent of the present invention and the agent for preventing, suppressing, or improving skin deterioration due to accumulation of the first AGEs of the present invention.
  • the cosmetic composition can improve, suppress, and reduce the deterioration of the entire skin caused by accumulation of AGEs in the skin (for example, change in skin color such as yellowish blur, reduction in firmness and transparency),
  • known anti-glycation components that can be added to cosmetics can be blended for the purpose of further enhancing the effects of the present invention, such as prevention and slowing down the progress (speed) of the deterioration of the entire skin.
  • Known anti-glycation components can be used singly or in combination of two or more.
  • the AGEs decomposing agent of the present invention is the AGEs decomposing agent of the present invention, and prevention, suppression, or improvement of skin deterioration due to accumulation of the first AGEs of the present invention.
  • the cosmetic composition has an antioxidant component, an anti-aging component, an anti-inflammatory component, a whitening component, a keratin softening component, a cell activation component, vitamins, a blood circulation promoting component, as long as the effects of the present invention are not hindered.
  • Other medicinal ingredients that can be added to cosmetics, such as moisturizing ingredients, ingredients that prevent and / or repair DNA damage, UV-absorbing ingredients, UV-scattering ingredients, cleaning ingredients, antibacterial ingredients, and astringent ingredients it can.
  • Other medicinal ingredients can be used alone or in combination of two or more.
  • Types of medicinal ingredients, particularly preferred types, and amounts used (contents) are described for the AGEs decomposing agent of the present invention and the agent for preventing, suppressing, or improving skin deterioration due to accumulation of the first AGEs of the present invention. That's right.
  • Active ingredients and other active ingredients in the agent for preventing, suppressing or improving skin deterioration due to accumulation of the second AGEs of the present invention, skin tension improving agent, and skin tone improving agent examples include the following combinations.
  • it contains a known anti-glycation component Amler extract, lychee seed extract, rose petal extract, maronier extract, maria thistle extract, neem extract, hydrolyzable tannin, L-arginine or salt thereof, lysine or salt thereof, Carnosine, ⁇ -lipoic acid, aminoguanidine or a salt thereof, aristine, or glucosamine;
  • antioxidant components are included, grape seed extract, grape leaf extract, ginseng extract, comfrey leaf extract, proanthocyanidins, ⁇ -tocopherol, ⁇ -tocopherol, ascorbic acid, sodium ascorbate phosphate, ascorbate phosphate ester Magnesium, ascorbyl tetraiso
  • soy protein When it contains an anti-aging component, hydrolyzed soy protein, retinol, retinol acetate, or retinol palmitate, When containing an anti-inflammatory component, Comfrey leaf extract, allantoin, dipotassium glycyrrhizinate, or stearyl glycyrrhetinate When it contains a whitening component, arbutin, hydroquinone, kojic acid, ascorbic acid, sodium ascorbate phosphate, magnesium ascorbate phosphate, ascorbyl tetraisopalmitate (ascorbyl tetra-2-hexyldecanoate), or tranexamic acid, When cell activation component is included, bilberry leaf extract, retinol, retinol acetate, or retinol palmitate, When vitamins are included, vitamins A (retinol, retinol acetate, retinol palmitate), vitamins
  • ginseng extract When containing a blood circulation promoting component, ginseng extract, tocopherol nicotinate, glucosyl hesperidin, or hesperidin, When moisturizing ingredients are included, chigaya root extract, hydrolyzed collagen, hydrolyzed elastin, MPC polymer glycerin, 1,3-butylene glycol, polyethylene glycol, dipropylene glycol, diglycerin, polyoxypropylene methylglucoside, trimethylglycine (betaine) ), Hydroxyethyl urea, acrylic acid / acrylamide / dimethyldiallylammonium chloride copolymer, hydrogenated lecithin, hyaluronic acid, sodium hyaluronate, acetyl hyaluronic acid, sodium acetyl hyaluronate, or sorbitol, When it contains a component having an action of preventing and / or repairing DNA damage, Artemia extract or DNA
  • higher fatty acid salts (particularly salts of higher fatty acids such as palmitic acid, lauric acid, myristic acid, stearic acid), N-acyl amino acid salts (particularly sodium N-lauroyl aspartate, potassium hydroxide) / N-coconut oil fatty acid potassium acylglutamate, coconut oil fatty acid acylglycine sodium, myristoyl glutamic acid), fatty acid alkanolamide (especially coconut oil fatty acid diethanolamide, coconut oil fatty acid monoethanolamide), amine oxide (especially coconut oil alkyldimethyl) Amine oxide, lauryldimethylamine oxide), imidazolinium betaine (especially 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolium betaine, N-coconut oil fatty acid acyl-N-carboxymethoxyethyl) Ru-N-carboxymethylethylenediamine disodium) If it contains an antibacterial
  • anti-glycation components antioxidant components, anti-aging components, anti-inflammatory components, cell activation components, vitamins, and moisturizing components.
  • antioxidant components it is preferable to combine known anti-glycation components, anti-aging components, and antioxidant components.
  • the cosmetic composition may be applied in the usual manner of use and the number of uses. Also, (1) use of a composition containing the component (a) and the component (b), (2) a composition containing the component (a) and a composition containing the component (b) Any use mode of the combined use of is suitable.
  • the use target of the agent for preventing, suppressing, or improving skin deterioration due to accumulation of the second AGEs of the present invention, the skin tension improving agent, and the skin color improving agent is not particularly limited. Suitable subjects include humans in whom the overall skin decline due to the generation and accumulation of humans, and humans whose entire skin tends to decline due to the generation and accumulation of AGEs.
  • the present invention relates to a composition
  • a composition comprising the component (a) and the component (b) described above, the deterioration of the skin caused by the accumulation of advanced glycation end products (for example, reduction of skin firmness, or The amount effective for prevention, suppression, or improvement of skin color change), and the method of prevention, suppression, or improvement of skin deterioration caused by accumulation of advanced glycation end products applied to human skin.
  • advanced glycation end products for example, reduction of skin firmness, or The amount effective for prevention, suppression, or improvement of skin color change
  • composition containing the component (a) and the component (b) is used for the deterioration of the skin due to the accumulation of advanced glycation end products (for example, reduction of skin firmness or skin color change). ) For prevention, suppression, or improvement. Also used for the manufacture of an agent for preventing, suppressing, or improving the deterioration of the skin caused by accumulation of advanced glycation end products (for example, reduction of skin firmness or skin color change). Can do.
  • Example 1-1 (Measurement of AGEs resolution) (1) Test sample (vegetable oil / fatty acid) Evening primrose oil was purchased from Oriza Yuka and Nisshin Oilio Group. Cario Calbrasiliense fruit oil was purchased from Croda Japan. ⁇ -linolenic acid and ⁇ -linolenic acid were purchased from Cayman Chemical Co. Linoleic acid and oleic acid were purchased from Wako Pure Chemical Industries. Docosahexaenoic acid (DHA) was purchased from ChromaDex, Inc. Evening primrose extract was purchased from Oriza Yuka.
  • DHA Docosahexaenoic acid
  • Detector UV absorptiometer (measurement wavelength: 260nm)
  • Column Inertsil ODS-3 (4.6 x 250 mm)
  • Column temperature Constant temperature flow around 30 ° C: 1.20 mL / min
  • Mobile phase Mobile phase A Trifluoroacetic acid (1 ⁇ 1000) solution diluted with water
  • Mobile phase B Trifluoroacetic acid (1 ⁇ 1000) solution diluted with acetonitrile mixture
  • the gradient program is shown in Table 1-1 below.
  • the PPD cleavage rate was the ratio (percentage) of the amount of benzoic acid produced after the actual reaction with the test material to the total amount of benzoic acid theoretically produced from PPD. The results are shown in Table 1-2 below.
  • Example 1-2 (Examination of influence on skin color) Evening primrose oil was purchased from Nisshin Oillio Group. The test site was marked by marking 2cm x 2cm sections on the forearm of adults in their 20s and 40s (4 people per group). Evening primrose oil was applied to four test sites twice a day (morning and evening) at 0.05 ml / division. The forearm area where nothing was applied in each subject was used as a control. The skin color (b * value) was measured using a spectrocolorimeter (manufactured by Minolta, CM-2002) before the start of application and 28 days after application. The b * value is an index of chromaticity, and the larger the value, the stronger the yellowness, and the smaller the value, the stronger the blueness.
  • the amount of change in the b * value after 28 days of application of the test sample is shown in Table 1-3 below and FIG. 1-1.
  • the numerical values in Table 1-3 and FIG. 1-1 are average values of changes in b * values derived from four measured values (total of 16 measured values) of four subjects.
  • Example 1-3 (Examination of influence on skin elasticity)
  • the test sample was applied to the subject's forearm. After application for 28 days, using a skin viscoelasticity measuring device (Cutometer SEM575, manufactured by Integral), the applied part of the skin is aspirated for 2 seconds at a pressure of 300 mbar and then opened for 2 seconds to measure the change in skin height. Thus, the elasticity of the skin was evaluated. The ratio (Ua / Uf) of the height recovery due to opening (Ua) to the skin height (Uf) at the time of maximum suction was used as an index indicating the elasticity of the skin.
  • Example 1-4 Example 1-4 (Examination of influence on moisture content of skin)
  • evening primrose oil was applied to the subject's forearm.
  • the moisture content of the skin at the application part was measured using an impedance meter (IBS, Skicon-200). The results are shown in FIGS. 1-4. It can be seen that the application of evening primrose oil increased the moisture content of the skin (moisturizing).
  • Examples 2-1 to 2-3 described below are agents for preventing, suppressing or improving skin deterioration due to accumulation of the second AGEs of the present invention, agents for improving skin tension, agents for improving skin color. This is an example.
  • Test Sample Lactic acid and a sodium lactate-containing lotion having the composition shown in Table 2-1 below were prepared by a conventional method.
  • Lactic acid and sodium lactate were purchased from Pulac Japan. Evening primrose oil was purchased from Nissin Oilio Group. In the following examples, a group in which only the skin lotion was applied, a group in which only evening primrose oil was applied, and a group in which evening primrose oil was applied after the skin lotion was applied were provided.
  • Example 2-1 (Examination of the effect on skin color) The test site was marked by marking 2cm x 2cm sections on the forearm of adults in their 20s and 40s (4 people per group). The test sample was applied to four test sites twice a day (morning and evening), with lotion of 0.05 ml / compartment and 0.05 ml of evening primrose oil / compartment.
  • the forearm area where nothing was applied in each subject was used as a control.
  • the skin color (b * value) was measured using a spectrocolorimeter (Minolta, CM-2002) before starting application and after 28 days.
  • the b * value is an index of chromaticity, and the larger the value, the stronger the yellowness, and the smaller the value, the stronger the blueness.
  • the amount of change in the b * value after 28 days of application of the test sample is shown in Table 2-2 below and FIG. 2-1.
  • the numerical values in Table 2-2 and FIG. 2-1 are average values of changes in b * values derived from the measured values (total of 16 measured values) of four subjects of four subjects.
  • Example 2-2 (Examination of influence on skin elasticity)
  • the test sample was applied to the subject's forearm.
  • a skin viscoelasticity measuring device Integral Co., Ltd., Cutometer SEM575
  • the applied part of the skin is aspirated for 2 seconds at a pressure of 300 mbar and then opened for 2 seconds.
  • Skin elasticity was evaluated by measuring the change in thickness.
  • the ratio (Ua / Uf) of the height recovery due to opening (Ua) to the skin height (Uf) at the time of maximum suction was used as an index indicating the elasticity of the skin.
  • Example 2-3 (Examination of influence on moisture content of skin)
  • the test sample was applied to the subject's forearm.
  • the moisture content of the skin at the application part was measured using an impedance meter (IBS, Skicon-200).
  • IBS impedance meter
  • Fig. 2-4 It can be seen that the application of the skin lotion containing lactic acid and evening primrose oil increased the water content of the skin compared to the control.
  • Formulation Examples 1-1 to 1-21 are formulation examples of the AGEs decomposing agent of the present invention and an agent for preventing, suppressing, or improving skin deterioration due to accumulation of the first AGEs of the present invention.
  • Cosmetic composition The unit of the numerical value in the formulation examples of the cosmetic composition below is "% by weight”.
  • Formulation Example 1-7 Latex Cariocarbrasiliense fruit oil 0.05 Meadow Foam Oil 0.8 Lychee seed extract 0.2 Lysine 0.5 Hydrolyzed soy protein 1 d- ⁇ -tocopherol 0.1 ⁇ -Tocopherol 0.9 Chigaya Root Extract 0.5 Polyoxypropylene methyl glucoside 0.1 Allantoin 0.005 Lactic acid 0.5 Dipropylene glycol 1 Glycerin 4 1,3-butylene glycol 10 Glyceryl monostearate 0.2 Polyoxyethylene cetyl ether 0.8 Tetra-2-ethylhexanoic acid pentaerythrit 3 Methyl polysiloxane 0.5 Ethyltrisiloxane 3 Acrylic acid / alkyl methacrylate copolymer 0.75 Carboxyvinyl polymer 0.001 Chelating agent appropriate amount Preservative (methyl paraoxybenzoate) appropriate amount pH adjuster appropriate amount perfume appropriate amount Water balance Total 100
  • Formulation Example 1-8 Cream Evening Primrose Oil 1 Shea fat 0.3 Retinol palmitate 0.5 d- ⁇ -tocopherol 0.005 ⁇ -Tocopherol 0.005 Nicotinamide 0.5 Hydrolyzed collagen 0.01 Hydrolyzed elastin 0.01 Hydrogenated soybean phospholipid 0.3 Hyaluronic acid 0.1 Glycerin 2 1,3-butylene glycol 5 Polyoxyethylene hydrogenated castor oil 3 Tri (caprylic / capric) glyceryl 2 Tetra-2-ethylhexanoic acid pentaerythrit 3 Squalane 7 Cetanol 1 Stearyl alcohol 0.5 Acrylic acid / alkyl methacrylate copolymer 0.3 Chelating agent Appropriate amount of preservative (methyl paraoxybenzoate, appropriate amount of methyl paraoxybenzoate) pH adjuster appropriate amount perfume appropriate amount Water balance Total 100
  • Formulation Example 1-9 Cream Shea Fat 5 ⁇ -linolenic acid 0.5 Linoleic acid 0.3 Rose petal extract 0.5 Hydrolyzed soy protein 0.8 Grape seed extract 0.1 Tocopherol nicotinate 0.3 Polyoxypropylene methyl glucoside 3 Panax ginseng extract 0.1 Bilberry leaf extract 0.1 Dipropylene glycol 1.5 Glycerin 2 1,3-butylene glycol 3.5 Polyethylene glycol 0.01 Polyoxyethylene hydrogenated castor oil 2 Glyceryl monostearate 1 Tri (caprylic / capric) glyceryl 5 Squalane 2 Liquid paraffin 1 Methyl polysiloxane 0.1 Cyclomethicone 0.1 Cetanol 2 Carboxyvinyl polymer 0.4 Chelating agent appropriate amount preservative (methyl paraoxybenzoate, appropriate amount phenoxyethanol) pH adjuster appropriate amount perfume appropriate amount Water balance Total 100
  • Formulation Example 1-12 Cleansing Cream Evening Primrose Oil 0.01 Lychee seed extract 0.005 Arginine 0.1 Hydrolyzed soy protein 0.5 d- ⁇ -tocopherol 0.01 Comfrey leaf extract 0.001 Glycyrrhizic acid 2K 0.1 Glycerin 0.01 1,3-butylene glycol 1 Diglycerin 5 Glyceryl monostearate 0.5 Polyglyceryl monostearate 2 Tri (caprylic / capric) glyceryl 10 Liquid paraffin 3 Light liquid paraffin 10 Ethyltrisiloxane 0.5 Stearyl alcohol 3 Carboxyvinyl polymer 0.5 Chelating agent appropriate amount preservative (methyl paraoxybenzoate, appropriate amount phenoxyethanol) pH adjuster appropriate amount perfume appropriate amount Water balance Total 100
  • Formulation Example 1-13 Cleansing Cream ⁇ -Linolenic Acid 1 Amler extract 0.01 Grape seed extract 0.01 Panax ginseng extract 0.1 Allantoin 0.0001 Dipropylene glycol 7 1,3-butylene glycol 0.01 Glyceryl monostearate 1 Monostearic acid POE sorbitan 2 Tetra-2-ethylhexanoic acid pentaerythrite 8 Glyceryl tri-2-ethylhexanoate 8 Squalane 1 Liquid paraffin 7 Methyl polysiloxane 2 Behenyl alcohol 1 Carboxyvinyl polymer 0.5 Chelating agent appropriate amount preservative (methyl paraoxybenzoate, appropriate amount propyl paraoxybenzoate) pH adjuster appropriate amount perfume appropriate amount Water balance Total 100
  • prescription examples 2-1 to 2-6 show the prevention, suppression, or improvement of skin deterioration due to the accumulation of the second AGEs of the present invention, the improvement of skin tension, the improvement of skin tone. It is a prescription example.
  • the unit of the numerical values in the following formulation examples of the cosmetic composition is “% by weight”.
  • Formulation Example 2-2 Transparent lotion Glycolic acid 0.5 Sodium lactate 5 Salicylic acid 0.05 Cario Calbrasiliense fruit oil 0.1 ⁇ -linolenic acid (Mortierella oil) 0.05 Carrot extract 0.1 Neem extract 0.001 Arbutin 1 Hydrolyzed soy protein 0.5 MPC polymer 0.05 Bilberry leaf extract 0.01 Amler extract 0.01 Diglycerin 2 Polyoxypropylene methyl glucoside 2 Dipropylene glycol 8 Polyoxyethylene hydrogenated castor oil 0.5 Preservatives (methyl paraoxybenzoate, appropriate amount phenoxyethanol) pH adjuster appropriate amount perfume appropriate amount Water balance ⁇ br/> Total 100
  • Formulation Example 2-4 Cream Salicylic acid 0.1 Citric acid 0.4 Sodium citrate 0.1 Evening primrose oil 1 Shea fat 1 Meadow foam oil 0.5 avocado oil 0.001 d- ⁇ -tocopherol 0.1 Nicotinamide 0.5 Hydrolyzed collagen 0.01 Carnosine 0.1 Brown algae extract 0.1 Neem extract 0.001 Tri (caprylic / capric) glyceryl 5 Tetra-2-ethylhexanoic acid pentaerythrit 3 Squalane 1 Behenyl alcohol 1 Stearyl alcohol 0.8 Alkyl methacrylate methacrylate copolymer 1.2 Hydroxypropyl methylcellulose 0.2 Hydrogenated soybean phospholipid 0.3 Polyoxyethylene sorbitan isostearate 3 Chelating agent appropriate amount preservative (methyl paraoxybenzoate, appropriate amount propyl paraoxybenzoate) pH adjuster appropriate amount perfume appropriate amount Water balance ⁇ br/> Total 100
  • Formulation Example 2-6 (A) Cosmetic lactic acid containing ingredients 1 Sodium lactate 0.8 Ascorbic acid 5 Diethylene glycol monoethyl ether 50 Propylene glycol 15 Dipropylene glycol 15 Diglycerin 5 Chelating agent appropriate amount pH adjuster appropriate amount perfume appropriate amount Water balance ⁇ br/> Total 100 (B) Cream evening primrose oil containing ingredients 2 Meadow foam oil 1 Shea fat 3 Toad extract 0.1 Glycerin 5 1,3-butylene glycol 5 Vaseline 5 Liquid paraffin 2 Glyceryl tri-2-ethylhexanoate 2 Tetra-2-ethylhexanoic acid pentaerythrit 4 Polyoxyethylene hydrogenated castor oil 1.8 Glyceryl monostearate 1.2 Carboxyvinyl polymer 0.3 Stearyl alcohol 2 Behenyl alcohol 2 Chelating agent appropriate amount preservative (methyl paraoxybenzoate, appropriate amount propyl paraoxybenzoate) pH adjuster appropriate amount perfume appropriate amount Water balance ⁇ br/
  • Unsaturated fatty acids, and pharmaceutically acceptable derivatives thereof, and vegetable oils containing these have AGEs-degrading activity, so adding AGEs to the skin by adding them to cosmetic or food compositions
  • AGEs-degrading activity so adding AGEs to the skin by adding them to cosmetic or food compositions
  • various diseases caused by AGEs can be improved.
  • a mixture of (a) lactic acid and / or a salt thereof and (b) AGEs degrading agent improves skin elasticity, improves the return of deformed skin, and makes the skin color like yellowish Improves taste and improves skin moisture. Therefore, the composition containing the above mixture can be suitably used as a cosmetic composition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne un agent de décomposition d'AGE et un agent pour prévenir, inhiber, ou améliorer la dégradation de la peau due à l'accumulation d'AGE, lesdits agents contenant, en tant que substance active : (i) un acide gras insaturé et/ou un sel pharmaceutiquement acceptable, un ester, un amide, et/ou un glycéride de celui-ci ; ou (ii) une huile végétale (huile d'onagre, huile de pequi, huile de graine de limnanthe, huile de karité, etc.) qui contient un acide gras insaturé et/ou un glycéride de celle-ci. Un agent qui contient (i) ou (ii), en plus des acide lactique, acide glycolique, acide salicylique, acide malique, acide citrique, acide phytique, et/ou un sel pharmaceutiquement acceptable d'un ou plusieurs desdits acides, est un agent plus efficace pour prévenir, inhiber, ou améliorer la dégradation de la peau due à l'accumulation d'AGE.
PCT/JP2010/056853 2009-04-17 2010-04-16 Agent pour prévenir, inhiber ou améliorer le vieillissement de la peau dû à l'accumulation de produits finaux de glycation avancée (age) WO2010119955A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201080012136.4A CN102355884B (zh) 2009-04-17 2010-04-16 由晚期糖基化终末产物的蓄积引起的皮肤老化的预防、抑制或改善剂
HK12107231.0A HK1166601A1 (en) 2009-04-17 2012-07-24 Agent for preventing, inhibiting, or ameliorating skin aging due to buildup of advanced glycation end products

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2009-101070 2009-04-17
JP2009101070A JP2010248150A (ja) 2009-04-17 2009-04-17 アドバンスド・グリケーション・エンド・プロダクツの蓄積による肌老化の予防、抑制、又は改善剤
JP2009101063A JP2010248148A (ja) 2009-04-17 2009-04-17 アドバンスド・グリケーション・エンド・プロダクツ分解剤
JP2009-101063 2009-04-17

Publications (1)

Publication Number Publication Date
WO2010119955A1 true WO2010119955A1 (fr) 2010-10-21

Family

ID=42982612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/056853 WO2010119955A1 (fr) 2009-04-17 2010-04-16 Agent pour prévenir, inhiber ou améliorer le vieillissement de la peau dû à l'accumulation de produits finaux de glycation avancée (age)

Country Status (3)

Country Link
CN (1) CN102355884B (fr)
HK (1) HK1166601A1 (fr)
WO (1) WO2010119955A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013099305A (ja) * 2011-11-10 2013-05-23 Pola Chemical Industries Inc 抗老化剤のスクリ−ニング方法
JP2015038184A (ja) * 2013-07-19 2015-02-26 白井松新薬株式会社 メイラード反応抑制機能または抗酸化機能を有する機能剤
CN105147563A (zh) * 2015-09-29 2015-12-16 珀莱雅化妆品股份有限公司 一种用于粉类化妆品的抗糖化颗粒及其制备方法
JPWO2016027837A1 (ja) * 2014-08-20 2017-07-20 株式会社林原 経口美容剤
JP2017210424A (ja) * 2016-05-24 2017-11-30 株式会社東洋新薬 化粧料、抗糖化組成物及び組成物
JP2019116421A (ja) * 2017-12-15 2019-07-18 ロレアル ヒドロキシ酸、塩基性アミノ酸、及びアミノ酸系界面活性剤を含む、ケラチン物質を処置するための組成物
JP2019147767A (ja) * 2018-02-28 2019-09-05 株式会社コーセー 化粧料及び皮膚外用剤
WO2019241728A1 (fr) * 2018-06-15 2019-12-19 Youhealth Biotech, Limited Composition et procédés de modulation de elovl2
CN111700818A (zh) * 2020-07-14 2020-09-25 瑞莱茵(北京)生物科技有限责任公司 一种祛皱抗衰人参多肽化妆水及其制备方法
CN115337230A (zh) * 2022-08-18 2022-11-15 宁波赛缪斯生物科技有限公司 一种基于抗衰老基因定制护肤品的方法与护肤品

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103961276A (zh) * 2014-01-08 2014-08-06 片仔癀（上海）生物科技研发有限公司 抗糖化化妆品组合物及含其的抗糖化化妆品
JP2016006036A (ja) * 2014-05-26 2016-01-14 アークレイ株式会社 ＡＧＥｓ分解剤およびその用途
EP3342396B1 (fr) * 2015-09-02 2023-04-12 Hayashibara Co., Ltd. Préparation externe dermatologique pour réduire le jaunissement cutané
JP6793944B2 (ja) * 2016-11-24 2020-12-02 Ｎｓマテリアルズ株式会社 携帯型測定器
CN109234305B (zh) * 2018-07-16 2021-08-03 浙江理工大学 一种棉花性状改良的方法
CN112557532A (zh) * 2020-11-27 2021-03-26 北京康立生医药技术开发有限公司 一种含茶氨酸组合物的检测方法
CN113712836A (zh) * 2020-12-30 2021-11-30 深圳市巴斯星科技有限公司 抗炎祛痘皮肤护理组合物及其制备方法和使用方法
CN112870313B (zh) * 2021-01-14 2022-08-05 纽斯葆广赛（广东）生物科技股份有限公司 一种抑制晚期糖基化终末产物表达和抑制血管硬化的组合物及其制备方法
CN113712875A (zh) * 2021-09-28 2021-11-30 蔻蔻琪生物科技(杭州)有限公司 一种纳米化抗糖化组合物及其制备方法与应用
CN113893203B (zh) * 2021-11-23 2023-06-20 湖北省麦诗特生物科技有限公司 一种含有抗衰老功效脂质体的面霜组合物及其制备方法和应用
CN114504022B (zh) * 2022-02-28 2024-01-23 贵阳学院 一种百香果保鲜剂及其制备方法与应用
CN115192491B (zh) * 2022-08-05 2023-09-26 广东北工商绿色护肤品研究院有限公司 一种化妆品组合物及其制备方法和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05286846A (ja) * 1992-04-03 1993-11-02 Kose Corp 皮膚老化防止用化粧料
JPH05286845A (ja) * 1992-04-03 1993-11-02 Kose Corp 皮膚老化防止用化粧料
JPH06192082A (ja) * 1992-08-31 1994-07-12 Eisai Co Ltd 細胞膜老化改善剤
JP2000072653A (ja) * 1998-08-28 2000-03-07 Shiseido Internatl Fr Sas 脂肪酸の化粧品への使用
JP2001122758A (ja) * 1999-10-22 2001-05-08 Pola Chem Ind Inc ＡＧＥｓ分解作用を有する老化肌防御、改善化粧料
JP2003073268A (ja) * 2001-08-31 2003-03-12 Almighty:Kk 細胞賦活剤及びそれを含有する皮膚外用剤
JP2004035424A (ja) * 2002-07-01 2004-02-05 Mitsukan Group Honsha:Kk メイラード反応抑制物質
JP2007119373A (ja) * 2005-10-26 2007-05-17 Arkray Inc メイラード反応生成物分解剤およびそれを用いた飲食品

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5286846B2 (ja) * 2008-03-12 2013-09-11 日立化成株式会社 導電性基板及びその製造方法、並びに銅配線基板及びその製造方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05286846A (ja) * 1992-04-03 1993-11-02 Kose Corp 皮膚老化防止用化粧料
JPH05286845A (ja) * 1992-04-03 1993-11-02 Kose Corp 皮膚老化防止用化粧料
JPH06192082A (ja) * 1992-08-31 1994-07-12 Eisai Co Ltd 細胞膜老化改善剤
JP2000072653A (ja) * 1998-08-28 2000-03-07 Shiseido Internatl Fr Sas 脂肪酸の化粧品への使用
JP2001122758A (ja) * 1999-10-22 2001-05-08 Pola Chem Ind Inc ＡＧＥｓ分解作用を有する老化肌防御、改善化粧料
JP2003073268A (ja) * 2001-08-31 2003-03-12 Almighty:Kk 細胞賦活剤及びそれを含有する皮膚外用剤
JP2004035424A (ja) * 2002-07-01 2004-02-05 Mitsukan Group Honsha:Kk メイラード反応抑制物質
JP2007119373A (ja) * 2005-10-26 2007-05-17 Arkray Inc メイラード反応生成物分解剤およびそれを用いた飲食品

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013099305A (ja) * 2011-11-10 2013-05-23 Pola Chemical Industries Inc 抗老化剤のスクリ−ニング方法
JP2015038184A (ja) * 2013-07-19 2015-02-26 白井松新薬株式会社 メイラード反応抑制機能または抗酸化機能を有する機能剤
JPWO2016027837A1 (ja) * 2014-08-20 2017-07-20 株式会社林原 経口美容剤
CN105147563A (zh) * 2015-09-29 2015-12-16 珀莱雅化妆品股份有限公司 一种用于粉类化妆品的抗糖化颗粒及其制备方法
CN105147563B (zh) * 2015-09-29 2017-11-28 珀莱雅化妆品股份有限公司 一种用于粉类化妆品的抗糖化颗粒及其制备方法
JP2017210424A (ja) * 2016-05-24 2017-11-30 株式会社東洋新薬 化粧料、抗糖化組成物及び組成物
JP2019116421A (ja) * 2017-12-15 2019-07-18 ロレアル ヒドロキシ酸、塩基性アミノ酸、及びアミノ酸系界面活性剤を含む、ケラチン物質を処置するための組成物
JP7086589B2 (ja) 2017-12-15 2022-06-20 ロレアル ヒドロキシ酸、塩基性アミノ酸、及びアミノ酸系界面活性剤を含む、ケラチン物質を処置するための組成物
JP2019147767A (ja) * 2018-02-28 2019-09-05 株式会社コーセー 化粧料及び皮膚外用剤
JP7051494B2 (ja) 2018-02-28 2022-04-11 株式会社コーセー 化粧料及び皮膚外用剤
WO2019241728A1 (fr) * 2018-06-15 2019-12-19 Youhealth Biotech, Limited Composition et procédés de modulation de elovl2
CN111700818A (zh) * 2020-07-14 2020-09-25 瑞莱茵(北京)生物科技有限责任公司 一种祛皱抗衰人参多肽化妆水及其制备方法
CN115337230A (zh) * 2022-08-18 2022-11-15 宁波赛缪斯生物科技有限公司 一种基于抗衰老基因定制护肤品的方法与护肤品

Also Published As

Publication number Publication date
HK1166601A1 (en) 2012-11-02
CN102355884B (zh) 2015-01-14
CN102355884A (zh) 2012-02-15

Similar Documents

Publication Publication Date Title
WO2010119955A1 (fr) Agent pour prévenir, inhiber ou améliorer le vieillissement de la peau dû à l'accumulation de produits finaux de glycation avancée (age)
JP2011102270A (ja) 抗糖化剤
JP2010248148A (ja) アドバンスド・グリケーション・エンド・プロダクツ分解剤
JP6058532B2 (ja) エンドセリン−１産生抑制用組成物、及び細胞増殖促進用組成物
JP5996156B2 (ja) 美肌用遺伝子発現促進剤並びにそれを用いた保湿用組成物及び美肌用組成物
FR2969496A1 (fr) Extrait de pulpe et/ou de peau d'avocat riche en polyphenols et compositions cosmetiques, dermatologiques et nutraceutiques le comprenant
CA2489308A1 (fr) Utilisation de la taurine pour le traitement de l'alopecie
FR2969495A1 (fr) Extrait de parties aeriennes de maca riche en polyphenols et composition le comprenant
KR20190112117A (ko) 피부 색소 침착 억제제
TW201300136A (zh) 美膚促進劑及其利用
JP2010248150A (ja) アドバンスド・グリケーション・エンド・プロダクツの蓄積による肌老化の予防、抑制、又は改善剤
JP2009161458A (ja) 細胞のアスコルビン酸類の取り込み促進剤
WO2019230233A1 (fr) Extrait de griffe du diable et variété de compositions le contenant, et procédé de production d'extrait de griffe du diable
JP5571280B2 (ja) 皮脂産生促進剤
JP6633847B2 (ja) 外用剤
JP2012036128A (ja) コラーゲン産生促進剤及びそれを用いた美肌用組成物
JP2007297343A (ja) 脂質代謝改善剤
JP2012207015A (ja) エラスターゼ活性阻害剤
JP4925692B2 (ja) 美肌用組成物
JP5308042B2 (ja) マンゴー抽出物
JP6909569B2 (ja) 肌質改善剤
JP2011068588A (ja) 体重増加抑制剤
WO2012008457A1 (fr) Composition pour application externe
JP7246965B2 (ja) サルコペニア肥満予防・改善剤
JP2012036174A (ja) 外用組成物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080012136.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10764537

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10764537

Country of ref document: EP

Kind code of ref document: A1